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ABSTRACT 
  
3 
	
Background:  Vascularised composite allografts (VCAs), such as face, hand and 
abdominal wall transplants, have resulted in excellent functional and quality-of-life 
outcomes.  The development of VCA tolerance protocols would obviate the need for 
immunosuppression and allow widespread use of this reconstructive modality.  But 
tolerance of VCA skin has been particularly difficult to achieve.  I hypothesised that 
sharing of MHC class I and/or class II between donor and recipient influences VCA 
tolerance.  
 
Methods:  Two large animal experimental models were used.  In model 1, MGH 
miniature swine recipients (n=8) underwent non-myeloablative conditioning and 
haematopoietic stem cell transplantation (HSCT), generating mixed chimeras across 
either a class I (n=4) or class II (n=4) MHC mismatch.  VCAs were transplanted at the 
time of HSCT.  In model 2, VCAs were transplanted onto animals already tolerant of 
heart and kidney transplants across haploidentical and full MHC barriers through 
regulatory pathways (n=4).  Serial biopsies of VCAs were performed to assess rejection 
and cellular infiltrate.  Flow cytometry was used to assess chimerism in the peripheral 
blood and tissues.  Immune responsiveness was assessed using mixed lymphocyte 
reaction, cell-mediated lymphocytotoxicity and alloantibody assays.   
 
Results:  In model 1, animals displayed stable mixed chimerism in lymphoid, myeloid 
and granulocyte lineages.  MHC class II-mismatched chimeras remained tolerant of 
VCAs (>500 days).  In contrast, MHC class I-mismatched chimeras experienced rejection 
of VCA skin, characterised by infiltration of recipient-type CD8+ T lymphocytes.  All 
animals demonstrated systemic donor-specific non-responsiveness in vitro, including 
after rejection episodes.  In model 2, animals rejected all components of VCAs placed 
across haploidentical and full MHC-mismatched barriers.  VCA rejection correlated with 
re-establishment of in vitro donor responsiveness.  Despite VCA rejection, tolerance of 
heart and kidney allografts persisted.  
 
Conclusions:  MHC matching of donor and recipient has not been considered in clinical 
VCAs to date.  This study shows that in a mixed chimerism model, MHC class I antigen 
mismatching mediates VCA skin rejection whereas robust VCA tolerance can be induced 
across MHC class II barriers.  In addition, we found that local regulation of immune 
tolerance is critical in long-term acceptance of VCAs.  Based on the tolerance of VCAs 
and non-vascularised skin grafts in MHC class II-mismatched chimeras, we hypothesised 
that establishing tolerance of allogeneic MHC class II antigens would facilitate more 
robust tolerance, via induction of regulatory pathways.  However, tolerance of VCAs was 
not seen in a large animal model in which regulatory tolerance of solid organs was 
established across MHC class II barriers.  Taken together, our results identify 
mechanisms underlying VCA skin tolerance, with important implications for future 
clinical strategies. 
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1. CLINICAL OUTCOMES OF VASCULARISED COMPOSITE 
ALLOGRAFT TRANSPLANTATION 
 
1.1 RECONSTRUCTIVE TRANSPLANTATION 
	
Over a million people in the UK are affected by disfigurements from burns, trauma, 
infections, malignancies and congenital anomalies. 1  The most extensive of these have a 
devastating and costly impact on lives. 2  The reconstructive ladder has provided the 
principles for surgical management of tissue loss, with free tissue transfer using 
microsurgical techniques, applied for severe disfigurement (Figure 1.1). 3  A cohort of 
people, nonetheless, exists for whom adequate restoration of form and function cannot be 
achieved.  
 
Figure 1.1.  The reconstructive ladder. 
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The use of transplants for reconstructive purposes would allow single-step 
reconstruction of complex anatomical structures.  Vascularised composite allografts (VCAs) 
are primarily vascularised units composed of multiple tissue types, including skin, muscle, 
blood vessel, nerve and bone.  Over the past 18 years, VCA transplants of the face, upper 
extremities, lower extremities and abdominal wall have been successfully performed (Figure 
1.2, Table 1.1). 4-7  Significant functional and quality-of-life improvements have been seen 
following these procedures. 6,8-10  However, in the context of life-saving solid organ 
transplants, a fundamental ethical question remains: are the life-enhancing benefits of VCAs 
justified by the risks of immunosuppression, which include opportunistic infections, 
malignancy and organ failure?  Strategies to offset the risks of immunosuppression would 
shift the risk-to-benefit ratio and allow widespread application of this promising 
reconstructive modality. 
Year Landmark 
1953 
1954 
1964 
1998 
2001 
2004 
2005 
2006 
2009 
2010 
2013 
2014 
First demonstration of tolerance of mouse skin grafts using haematopoietic chimerism. 
First clinical kidney transplant. 
Hand transplant attempted in Ecuador.  Rejected after 2 weeks. 
First successful unilateral hand transplant. 
First abdominal wall transplant. 
First bilateral hand transplant. 
First partial face transplant. 
First unilateral lower limb transplant. 
Bone marrow-based immunosuppression minimisation protocol initiated in hand transplantation. 
First bilateral lower limb transplant 
Tolerance of VCAs demonstrated in large animals using mixed chimerism. 
First successful penis transplant. 
Table 1.1.  Timeline of landmark events in reconstructive transplantation. 
18 
	
 
Figure 1.2.  VCAs performed as of 2016.  
VCAs performed to date have included face, abdominal wall, upper extremity, lower 
extremity and penis transplants. 
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1.2 CURRENT STATUS OF CLINICAL VCAs 
 
1.2.1 Face transplants 
Severe facial defects are associated with psychological concerns, social isolation and 
functional impairments involving communication, feeding and breathing. 11-13  The 
complexity of facial structures provides significant challenges for reconstruction using 
conventional techniques, and multiple procedures often result in an inanimate, insensate and 
suboptimal aesthetic outcome.  As a result, the inaugural clinical face transplant in November 
2005 represented a paradigm shift in the reconstructive options for severe facial defects. 5,14  
In the following decade, 37 face transplants have been performed across the world in 
recipients who have sustained extensive facial damage from ballistic injuries, burns, 
neurofibromatosis, malignancy and animal attacks (Table 1.2). 9,10,15  
An evolution in the surgical approach to facial transplantation has been seen, with the 
initial cases using partial face transplants and the later cases involving total face transplants, 
inclusive of underlying bone segments. 9,10,15  Surgical progress was supported by preclinical 
studies to define the vascular anatomy and procurement technique for full face transplants; in 
particular, to ensure that structures of the central face, including the maxilla, hard palate and 
oral mucosa could be accurately harvested and adequately perfused. 16-19  In addition to 
allowing VCAs to be applied to the most extreme facial defects, the use of larger face 
transplants has identified principles for better clinical outcomes.  By using face transplants 
containing bony segments with the tooth-bearing segments of the maxilla and mandible, even 
for deficits of a single jaw, more accurate dental occlusion can be achieved to the benefit of 
speech and mastication. 9,20,21  The inclusion of bone-containing vascularised bone marrow 
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(VBM), such as the mandible, has been shown to be associated with fewer acute rejection 
episodes and better graft survival. 22  The use of more extensive face transplants, with larger 
bony segments, has increased donor retrieval time.  Protocols have, thus, been developed for 
concurrent procurement of VCA, thoracic and abdominal organs, allowing facial 
transplantation to become more integrated with solid organ transplantation. 23-25  
Clinical outcomes of facial transplantation have been favourable compared with 
conventional reconstructive methods.  Facial sensation has been restored following VCAs 
(Table 1.2).  Recovery of thermal and mechanical sensation can occur as quickly as 3 months 
after surgery, with full sensory recovery consistently occurring by 8 months. 14,25-32  Sensory 
recovery following face transplants has often exceeded expectations, particularly in cases 
where nerve coaptation was not performed. 28,31,33  Restoration of sensation has been seen 
when no branches of the trigeminal nerve were repaired, with interconnections between the 
facial and trigeminal nerve proposed as an explanation. 34  Similarly, sensory recovery has 
been reported when bilateral donor mental nerves were placed next to the mental foramen 
without repair. 27,28  These cases demonstrated that recipients with extensively damaged or 
atrophied sensory nerves could recover sensation with face transplants. 
Motor recovery following face transplants has generally occurred more slowly than 
sensory re-innervation (Table 1.2). 9,10,15  However, initial motor function has been seen as 
early as 2 to 3 months post-operatively, with lip occlusion achieved by 6 to 8 months. 28  
Continued motor recovery has been noted years after the face transplant, with the first 
recipient reported to have improvements at 8 years. 35  Unlike sensory nerve function, motor 
abilities have required satisfactory motor nerve coaptation. 31 
21 
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Table 1.2.  Outcomes of clinical face transplants in 2016. 
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Sensory and motor recovery has resulted in significant functional benefits 
following face transplants (Table 1.2).  All recipients have seen improvements in abilities 
to eat, smell and feel, while breathing, speaking and facial expressions were improved in 
the majority of cases. 9,10,15,36  All patients dependent on gastrostomy and 91% of patients 
dependent on tracheostomy were decannulated following facial transplantation. 36  
Functional recovery has been aided following facial transplantation by reduction in 
chronic pain levels from scarred and contracted tissues. 33  
Restoration of intrinsic facial functions has, as a corollary, improved quality-of-
life. 14,29,37  Face transplant recipients have re-integrated into society and returned to 
employment. 27,28  The effectiveness of facial transplantation has been demonstrated by 
measurable improvements in depression, body image and interactions with observers. 38      
 
1.2.2 Hand and upper extremity transplants 
The first modern upper extremity transplant occurred in Lyon, France in 1998, 
based on the superior functional outcomes of upper limb replantation compared with 
prosthetic devices. 4,39,40  Hand and upper extremity transplants are now the most common 
type of VCA.  Currently, there have been 74 recipients of 111 hand or upper extremity 
allografts, including 4 cases in which the transplants were performed concomitantly with 
other VCAs (Table 1.3). 8  
Amputation or severe disfigurement of both upper extremities significantly 
impacts quality-of-life and is the most widely accepted indication, among hand surgeons, 
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for VCA. 41  Transplants have been performed at varying levels from isolated digit to 
transhumeral upper extremities and have included unilateral and bilateral allografts. 8,42  
Surgical technique has been based on replantation procedures, involving 
osteosynthesis followed by revascularisation, tendon/muscle repair, nerve coaptation and 
skin closure. 43  Transplantation, however, is done on an elective basis, allowing pre-
operative work-up with electromyography, angiography, nerve conduction velocities and 
computed tomography (CT)/magnetic resonance imaging (MRI).  The surgical approach 
may also be planned to optimise outcomes by modifying the levels at which coaptation of 
the bones, vessels, muscles and nerves are performed.  Ulnar shortening osteotomy has 
been used to create precise, oblique bone surfaces, which maximise the area of recipient-
to-donor bone contact and create maximal bone compression, thus reducing the risk of 
osseous non-union. 44  An elegant modification of surgical technique was used in a recent 
unilateral left hand transplant in a burns patient with circumferential injury and deficiency 
of cutaneous veins.  A volar forearm fasciocutaneous extension flap, including radial 
artery and basilic vein, was raised with the allograft.  This allowed proximal vascular 
anastomoses at the level of the antecubital fossa with distal ulnar and median 
neurorrhaphies. 45     
To date, all recipients of isolated upper extremity transplants have survived except 
1 patient from Mexico, who died in the perioperative period following bilateral hand 
transplantation, giving an overall patient survival rate of 98.5%. 8  Overall, 14 recipients of 
hand or upper extremity transplantation in isolation have lost 16 allografts due to patient 
mortality, acute limb loss or chronic limb loss. 8,42,46-49  In the USA, western Europe and 
Australia, 45 patients have received 69 isolated upper extremity transplants (21 unilateral 
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and 24 bilateral). 8,42,46,47,50-52  No patient mortality has been seen in this cohort and 6 hand 
allografts were lost due to patient non-compliance with immunosuppression or 
uncontrolled rejection (Table 1.3). 8,46,47  
Country Total 
Patients 
Number Of 
Centres 
Unilateral 
Cases 
Bilateral Cases Transplanted 
Hands 
Lost Hands Causes Of Loss 
United 
States 
23 8 13 10 33 7 IS non-compliance 
Chronic rejection 
Concomitant VCAs 
China 12 6 9 3 15 7 IS non-compliance 
France 7 2 1 6 13 3 IS non-compliance 
Concomitant VCAs 
Poland 6 1 5 1 7 1 Arterial insufficiency 
Austria 5 1 1 4 9 0  
Spain 4 2 0 4 8 0  
Turkey 4 2 0 4 8 4 Concomitant VCAs 
Italy 4 2 3 1 5 0  
Mexico 2 1 0 2 4 2 Post-op patient death 
Germany 1 1 0 1 2 0  
India 1 1 0 1 2 0  
Australia 1 1 1 0 1 0  
Belgium 1 1 1 0 1 0  
Iran 1 1 1 0 1 0  
Malaysia 1 1 1 0 1 0  
UK 1 1 1 0 1 0  
Totals 74 32 37 37 111 24  
Table 1.3.  World experience of hand and upper extremity transplantation in 2016.  
IS, immunosuppression. 
 
In general, after 1 year 100% of patients develop protective sensibility, 90% 
develop tactile sensibility and 84% develop discriminative sensibility. 42  Motor recovery 
begins with extrinsic muscle function, allowing gripping activities.  Intrinsic muscle 
recovery starts between 9 and 15 months in most patients. 42  Functional MRI has found 
amputation-induced cortical reorganisation within the motor cortex is reversed following 
hand transplantation. 53  As with face transplants, progressive motor improvements have 
been seen for years following transplantation. 54,55  
The precise extent of motor and sensory recovery has depended on level of 
transplantation.  More distal transplants have resulted in better functional outcomes; these 
recipients have frequently recovered intrinsic hand function and discriminative sensation.  
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More proximal level transplants have resulted in limited intrinsic hand function, less 
protective sensation and weaker grip strength. 8,48,56,57  However, motor and sensory 
recovery of proximal level transplants has exceeded expectations.  Due to the significant 
disability of proximal amputations, transhumeral upper extremity transplants have had a 
greater functional impact than more distal allografts. 8  Recovery of motor and sensory 
function has allowed recipients to perform activities of daily living including eating, 
dressing, driving, gripping, shaving, writing and even riding a motorcycle. 42  
Heterogeneous tools have been used to objectively measure functional outcomes, 
including the Disabilities of the Arm, Shoulder and Hand questionnaire (DASH), Hand 
Transplant Scoring System (HTSS) and Chen scores.  Collective analysis of DASH scores 
demonstrates that upper extremity transplantation results in significantly reduced 
disability, particularly for bilateral transplants, in the majority of recipients.  Similarly, 
assessment of function using Chen scores and the HTSS revealed improved functional 
outcomes post-transplant. 8,42,46-48,51,54,58  
 
1.2.3 Abdominal wall transplants 
Abdominal wall transplantation has been performed at the time of solid organ 
transplantation to close the abdominal wall.  Closure after intestinal or multivisceral 
transplants is technically challenging due to tissue loss during midgut resection, scarring 
from previous laparotomies or stomas and the presence of multiple enterocutaneous 
fistulae.  In up to 20% of cases, abdominal wall closure is not possible and secondary 
surgical procedures are required. 6,59  
27 
	
In the first cases of abdominal wall transplantation, VCAs consisting of the rectus 
abdominis muscles, investing fascia and overlying subcutaneous tissue and skin were 
supplied by femoral and iliac vessels. 6  Subsequently, direct microsurgical anastomosis of 
donor and recipient inferior epigastric vessels has been described. 60,61  A recent series of 
abdominal wall transplants has used intermittent perfusion of the VCAs using the recipient 
forearm vessels to minimise cold ischemia time during intestinal transplantation. 62  The 
iterations in surgical technique have allowed more efficient VCA retrieval, reduced 
ischaemia time and provided back-up options in the event of recipient compromise at the 
end of solid organ transplantation.  Developments in surgical technique have incorporated 
abdominal wall transplants into donor and recipient solid organ transplantation protocols 
and established pathways for future VCA teams.    
Cases of abdominal wall VCAs have not been well reported.  Currently 20 
allografts in 19 patients have been documented, including 4 paediatric cases. 61,63  The 
majority of, but not all, recipients have received abdominal wall transplants from the same 
donor as solid organ allografts.  Two allografts were lost due to vascular thrombosis on 
post-operative day (POD) 1 and 6. 61  In the remaining cases, coverage of intestinal and 
multivisceral transplants permitted expedited recovery.  At long-term follow-up, 9 out of 
20 patients are alive, with deaths unrelated to abdominal wall transplantation. 61,63  Eight 
of these patients still have abdominal wall VCAs.  In their case series, the Oxford group 
noted that rejection episodes of VCA skin preceded rejection of the intestinal transplant. 63  
Subsequently, VCAs consisting of small skin paddles were used as sentinel flaps for 
intestinal transplants or multivisceral transplants. 64  Treatment of rejection episodes 
affecting the sentinel VCAs resulted in reduced occurrence of solid organ transplant 
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rejection.  This has raised interest in the possible use of skin-containing VCAs as 
rejection-monitoring aids for conventional solid organ transplants. 
 
1.2.4 Lower extremity transplants 
It is estimated that there are up to 200,000 lower extremity amputees in the UK. 65  
But lower extremity transplants are controversial, with just a handful of cases to date. 7,66  
Bilateral lower limb amputees, including those with proximal, above-knee stumps, are 
able to achieve very good ambulation with modern prostheses.  On the other hand, lower 
extremity VCAs would require prolonged rehabilitation and functional outcomes are 
unknown. 67  
Despite these considerations, VCAs may still offer advantages. 68  First, lower 
extremity transplants, in contrast to prostheses can restore protective sensibility and 
proprioception, aiding ambulation. 68,69  This is likely to be enhanced by the neurogenic 
effect of immunosuppressive therapy. 70  Second, lower extremity transplantation may 
benefit patients suffering from residual limb or phantom limb pain, which is estimated to 
affect up to 85% of lower limb amputees. 71  Finally, the restoration of lower limb 
circulation may also reduce the risk of cardiovascular disease. 72  
Isolated lower extremity transplantation has been performed twice (Table 1.4).  
The first case, in 2006, was a unilateral full lower limb VCA between ischiopagus 
conjoined twins. 66  No post-operative immunosuppression was required.  After 6 years, 
motor re-innervation of the proximal large muscle groups of the thigh had resulted in good 
hip flexion, knee flexion and knee extension.  Ankle plantarflexion and dorsiflexion was 
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limited.  Good sensation was present throughout the limb.  Motor and sensory function 
was associated with ability to walk, run and hop, using a supportive brace. 73  The second 
case, in 2011, was a bilateral lower extremity transplant performed at the bifemoral level. 7  
The patient was a 22-year-old male who had been unable to tolerate prostheses due to pain 
and socket instability.  At 1 year follow-up there was active knee extension, knee flexion 
and ankle plantarflexion.  Ambulation was possible by 9 months with the use of rigid 
walking boots and parallel bars. 7  The lower extremity allografts were subsequently 
amputated after the patient was unable to continue taking immunosuppressant medication 
due to other co-morbidities.  
The surgical feasibility and potential functional benefits demonstrated by the initial 
lower extremity transplants have resulted in established VCA centres to recruit candidate 
patients.  It is, thus, likely that lower extremity transplants will continue to be performed 
in the future. 
 
Team Date Location Recipient Transplant Sensory 
Recovery 
Motor Recovery Functional 
Recovery 
Current 
Status 
Zuker May 
2006 
Toronto, 
Canada 
3 months, F Unilateral full 
right leg 
At 6 years – 
reduced light 
touch 
sensation in 
proximal limb 
but no 
functional 
deficit.  No 
neuropathic 
pain. 
At 6 years - full range 
passive movement, good 
hip abduction and 
flexion, good knee 
flexion/extension, limited 
hip extension and ankle 
dorsiflexion/plantarflexion 
Walking with a 
brace, able to run 
and hop, 
performing 
normal activities 
Patient alive, 
no issues with 
transplant 
Cavadas July 
2011 
Valencia, 
Spain 
22 yrs, M Bilateral 
transfemoral 
At 1 year – 
Tinel’s test 
positive at feet.  
Objective 
sensory 
assessment 
not performed. 
At 1 year - full range of 
passive movement, 
bilateral extension lag in 
knees.  Active knee 
flexion and ankle 
plantarflexion bilaterally. 
At 1 year – 
walking between 
parallel bars, 
using rigid ankle-
foot orthoses. 
Legs 
amputated 
subsequent to 
1 year report, 
due to co-
morbidities. 
Table 1.4.  World experience of lower extremity transplantation in 2016. 
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1.2.5 Concomitant VCA transplants 
The aetiologies of severe disfigurement often affect several anatomical areas, 
making simultaneous transplantation of multiple VCAs an interesting reconstructive 
solution.  However, concomitant VCA transplantation is considered the most complex 
type of reconstructive transplantation, due to the surgical, immunological and 
rehabilitation challenges (Table 1.5). 74,75 
 
Type Complexity Examples Characteristics 
I Low Flexor tendon, tongue, uterus, 
vascularised nerve 
No skin 
Low antigenicity 
II Moderate Abdominal wall, ear, genitalia, larynx, 
scalp, trachea, vascularised knee joint 
May contain skin 
Absent or minimal rehabilitation 
III High Upper extremity, lower extremity, face Requires a multidisciplinary team and 
complex rehabilitation 
Significant psychological obstacles 
Complex cortical reorganisation occurs 
IV Maximum Concomitant VCAs High mortality risk 
Extremely difficult rehabilitation 
Unknown functional outcomes 
Table 1.5.  The Gordon classification for complexity of VCAs.  
(adapted from Siemionow et al. 75) 
 
In the context of isolated VCAs, concomitant VCA transplantation has several 
additional surgical challenges.  These include prolonged operating and ischaemia times, 
and the need for extensive blood transfusions. 74,75  Reperfusion of multiple, large VCAs 
significantly increases intravascular volume, creating hypovolaemia, ischemia-reperfusion 
injury and electrolyte imbalance. 76,77  Donor-related issues must also be considered.  The 
harvest of multiple VCAs without compromising life-saving solid organs poses significant 
physiological and logistical challenges for procurement teams.  The restoration of donor 
31 
	
integrity is also likely to be more difficult, meaning concomitant VCAs may be less 
acceptable to consenting donor families. 
The antigen load involved in concomitant VCA transplants is significantly greater 
than isolated allografts. 78  While clinical and large animal studies of organ transplantation 
have shown a beneficial effect of larger transplants, the immunological effect of the 
antigen load in concomitant VCAs is unknown.  79,80  
Clinical concomitant VCA transplants have, so far, been attempted on 4 occasions 
with poor outcomes (Table 1.6). 76  The first case, in 2009, involved a full face and 
bilateral below elbow transplant in a 37-year-old man. 28  The patient developed multi-
drug resistant Pseudomonas aeroginosa infection of face and left hand allografts, resulting 
in tissue necrosis treated by surgical excisions and antibiotic therapy.  On POD 33, the 
patient suffered airway obstruction and cardio-respiratory arrest during treatment of septic 
haemorrhage.  Following a course of intensive care therapy, the patient died on POD 65. 28 
The second case involved concomitant face and bilateral hand transplant in 57-year-old 
woman. 26  In the perioperative period, the patient developed sepsis, secondary to 
aspiration pneumonia, resulting in ischemia and amputation of both hands.  This patient 
was discharged from the hospital on POD 38 and has had a well-functioning facial 
allograft. 26  The third case, in 2012, was a triple limb transplant in a 34-year-old man, 
consisting of bilateral hand and unilateral lower extremity.  Specific details of the case are 
unknown, but this patient is known to have died a few months after the transplant. 76  The 
fourth case, in 2012, involved a quadruple limb transplant in a 27-year-old man. 81  During 
the surgery, the patient became progressively more acidotic, hyperkalaemic and 
hyperphosphataemic.  At the end of the case, the patient suffered cardiac arrest.  
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Spontaneous circulation was re-established with sternotomy and cardiopulmonary support. 
In the following days, the metabolic status persisted and the patient received a total of 200 
units of transfused blood.  Despite amputation of all VCAs, the patient died on POD 4. 81   
Team Date Location Recipient Transplant Complications Current 
Status 
Lantieri March 2009 Paris, 
France 
37. M Face and bilateral 
below elbow 
upper limbs 
Pseudomonas 
infection of 
transplanted tissues. 
Cardiorespiratory 
arrest 
Dead – POD 
65 
Pomahac May 2011 Boston, 
USA 
57, F Face and bilateral 
hands 
Post-operative sepsis 
and ischaemia of 
hands 
Patient alive, 
hands 
removed.  
Good facial 
recovery. 
Ozkan January 2012 Antalya, 
Turkey 
34, M Bilateral hand 
and unilateral 
lower limb 
Not reported Dead - 3 
months 
Nasir February 2012 Ankara, 
Turkey 
27, M Bilateral 
transhumeral 
upper limbs and 
bilateral 
transfemoral 
lower limbs 
Peripoerative 
acidosis, 
hyperkalaemia, 
hyperphosphataemia. 
Post-operative 
cardiorespiratory 
arrest. 
Dead – POD 
4 
Table 1.6.  World experience of concomitant VCA transplantation in 2016. 
 
Mortality or allograft loss has been seen in all concomitant VCA cases.  This 
demonstrates the risks and challenges posed by multiple, simultaneous VCAs.  However, 
concomitant VCA transplantation represents an intriguing therapeutic option, with 
potential for significant improvement in quality-of-life.  Some existing VCA centres have, 
thus, taken the position that further translational, large animal research and protocol 
development must be done before future attempts at concomitant VCAs. 76,77 
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1.3 COMPLICATIONS OF VCAs  
	
Surgical feasibility of face, hand and upper extremity, abdominal wall and lower 
extremity transplants has been demonstrated.  VCA-related complications have been 
largely associated with the burden of immunosuppression.  Immunosuppression protocols 
have varied between institutions, but largely consisted of induction therapy with anti-
thymocyte globulin (ATG) or anti-interleukin-2 and alemtuzumab, followed by 
maintenance therapy with mycophenolate mofetil (MMF), tacrolimus and steroids. 
8,9,15,42,82  Patient non-compliance with immunosuppressive medication correlated with 
poor outcomes and allograft loss.  The second recipient of a face transplant, in China, died 
27 months after the procedure following discontinuation of medication. 9,10,15  The world’s 
first recipient of a hand transplant and 6 of 12 hand transplant recipients in China have lost 
allografts due to medication non-compliance. 49,83  
In VCA patients who have remained compliant with immunosuppression, drug-
related side effects have been frequently observed.  Opportunistic infections have been 
seen in face, upper extremity and lower extremity transplant recipients, including 
symptomatic drug-resistant cytomegalovirus (CMV) infections, Clostridium difficile 
colitis, herpes simplex blisters, herpes zoster, cutaneous mycosis and bacterial infections 
of the transplanted tissues. 9,10,42  Metabolic complications including new-onset insulin-
dependent diabetes, renal dysfunction requiring haemodialysis, aseptic necrosis of the hip 
requiring bilateral joint replacement, hypertension and Cushing’s syndrome have been 
reported. 9,10,42  
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The development of malignancies has been seen after VCA transplantation.  An 
Epstein-Barr virus-related B cell lymphoma has been seen in a face transplant recipient, 
affecting the liver, spleen, pancreas, lungs and lymph nodes.  Disease remission was 
achieved using rituximab therapy. 84  Death of a HIV-positive face transplant patient 
occurred following recurrence of a previously resected squamous cell carcinoma. 9  In situ 
cervical carcinoma was detected in the first face transplant recipient, which was 
successfully treated with excision. 85  Among hand transplant recipients, the occurrence 
basal cell carcinoma of the nose has been reported. 42  Post-transplant lymphoproliferative 
disorder (PTLD) has been seen in a hand transplant and an abdominal wall transplant 
recipient. 42,60  
Despite the use of immunosuppressants, almost all VCA recipients, irrespective of 
VCA type or size, have experienced acute rejection episodes characterised by an 
erythematous maculopapular skin rash and confirmed by histology. 7,9,42,61  These have 
been treated with prompt boluses of steroids.  High-grade, steroid-resistant episodes have 
required additional drugs, including basiliximab, alemtuzumab or ATG. 42  Topical 
immunosuppression has been used as an adjunct treatment to systemic drugs. 86,87  Loss of 
hand transplants from chronic rejection, characterised by intimal hyperplasia, has been 
reported by groups from Lyon, Wroclaw, Louisville and UCLA (Table 1.3). 88,89  The 
mechanisms contributing to chronic rejection of VCAs are poorly understood, particularly 
regarding antibody-mediated rejection and graft fibrosis.  However, the incidence of 
chronic rejection has been lower than predicted, with early hand transplant recipients over 
15 years post-transplant. 90-92 	  
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1.4 POTENTIAL AND LIMITATIONS OF VCA 
	
VCAs uphold the Harold Gillies principle of “replacing like with like” and allow 
single step restoration of form and function to patients with severe disfigurements.  The 
clinical outcomes of VCAs demonstrate the potential for reconstructive transplantation to 
achieve superior functional and aesthetic improvements in comparison with autologous 
reconstruction. 8-10  At the start of the VCA era, there were concerns that surgical failure of 
VCAs would require removal of the transplanted tissue, placing the recipient at the bottom 
of the reconstructive ladder. 92,93  However, the surgical outcomes of VCAs have been 
overwhelmingly successful, with more extensive transplants performed than predicted.  
This demonstrates the potential for use of VCAs in patients with no other reconstructive 
alternative.   
Ongoing improvements in motor function many years after transplantation and the 
restoration of basic functions and activities of daily living have provided significant 
quality-of-life benefits for VCA recipients. 8,36,85  Despite this, it is not clear whether 
VCAs will be widely adopted and become a standard-of-care therapy.  Deaths seen in 
recipients of large VCAs highlight the complications of these ambitious cases.  In 
addition, the tendency of transplanted skin to reject has been demonstrated with the 
frequency of acute rejection episodes in VCA recipients. 8-10  The impact of chronic 
rejection remains an unknown entity but is likely to become clearer over the coming years 
as VCA recipients maintain their transplants over longer periods of time.  It is also 
important to realise that successful VCA outcomes have been reliant on motivated patients 
who closely engage with VCA teams.   
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The most common type of VCA performed to date has been upper extremity and 
hand transplantation.  The development of prostheses in these areas has been an exciting 
field, driven by the United States military. 94  While VCAs have the considerable 
advantage of sensory discrimination, newer prosthetic limbs are being developed with 
sensory feedback.  These prostheses would offer patients an attractive alternative to VCAs 
and avoid the use of immunosuppressive medications and extensive rehabilitation.  
Ongoing development of upper limb transplantation must, thus, be considered alongside 
improvements in prosthetic technology. 
 
1.5 EVALUATING VCA PROGRESS TO DATE 
	
The ethical debate surrounding the introduction of VCAs is similar to that which 
followed the start of solid-organ transplants.  Renal and liver transplants are now well-
accepted treatment options but the introduction of both these transplant modalities was 
accompanied by frequent complications and mortality. 95-97  In contrast, less overall 
mortality has been observed in the early experience of VCA transplantation, and overall 
clinical outcomes have far exceeded early expectations. 8,9,92  It is important to note, 
however, that VCAs are not life-saving.  While VCAs have had clear psychological and 
quality-of-life benefits, occurrences of significant complications as a result of surgery, 
rejection or immunosuppression-related complications will be controversial.  As a 
consequence, developing strategies to limit or eliminate the burden of 
immunosuppression, whilst preventing rejection, is central to the future development of 
the field.   
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 Currently small overall volumes of VCAs are performed every year, reflecting the 
technical and scientific expertise required to perform these cases.  The limited number of 
clinical VCA teams must be encouraged to share their data and accurately report their 
outcomes in the literature.  To date, the establishment of professional VCA societies in 
Europe and America, designated VCA meetings and publication of outcomes have 
allowed robust patient selection to be identified as the single best predictor of outcome.  
Well-motivated patients who are able to engage with the patient selection process, adjust 
to surgery and comply with immunosuppressive medications and rehabilitation have 
achieved the best outcomes.  Further collaboration between VCA centers and candid 
reporting of all patients will allow reliable evaluation of long-term outcomes and 
development of standardised patient selection methods and tools to assess functional and 
immunological results.   
The first 18 years of the VCA era have demonstrated the exciting potential for this 
reconstructive option to become a gold standard for patients with severe disfigurements.  
However, this will require challenges to be overcome in the future.  Given the complexity 
of the surgical, rehabilitation and immunological factors, the cautious expansion of the 
VCA field is prudent, with cases evaluated and performed only by experienced multi-
disciplinary teams.   
	
1.6 SUMMARY OF CLINICAL OUTCOMES OF VCAs 
 
VCA transplantation is a promising reconstructive option for those with severe 
tissue defects.  Surgical feasibility of face, hand and upper extremity, abdominal wall and 
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lower extremity transplantation has been demonstrated.  Recipients have, largely, 
experienced restoration of function and improvement in quality-of-life.  Complications, 
however, have been seen and mostly related to use of immunosuppressive medications or 
rejection episodes.  With increasing numbers of VCA centres being formed around the 
world, it is likely that VCA transplants will be performed with increasing frequency in the 
future.  
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2. TRANSPLANT TOLERANCE OF VCAs 
	
2.1 TRANSPLANT TOLERANCE 
 
In the context of life-saving solid organ transplants, the fundamental question 
surrounding VCAs is whether the life-enhancing benefits of transplantation are justified 
by the risks of life-long immunosuppression.  Transplant tolerance is the specific absence 
of a destructive immune response to a transplanted tissue in the absence of 
immunosuppression. 98  Induction of transplant tolerance would obviate the need for 
chronic immunosuppression, fundamentally shifting the risk-to-benefit balance of VCAs 
and allowing widespread application of this reconstructive modality. 
Strategies to generate tolerance of genetically disparate allografts have been a 
major goal of transplantation research for 70 years. 99  A number of successful approaches 
have been developed in rodent models, including donor specific transfusion (DST), anti-
major histocompatibility (MHC) antibodies, calcineurin inhibitors, anti-lymphocyte 
serum, total lymphoid irradiation, genetic manipulation, co-stimulatory blockade, T 
regulatory cell (Treg) therapy, mesenchymal stem cell (MSC) therapy, dendritic cells and 
oral tolerance. 100  Differences in tissue expression of MHC class II antigens, levels of 
heterologous memory T cells and resilience to conditioning regimens make induction of 
allograft tolerance in large animal models and clinical trials more challenging. 100  Mixed 
chimerism remains the only strategy to have achieved transplant tolerance in small animal 
studies, large animal studies and clinical trials.  
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2.2 MIXED CHIMERISM 
	
The induction of chimerism is used in the treatment of haematological cancers.  
This involves ablation of the recipient bone marrow, including the malignant cells, 
followed by complete replacement with donor bone marrow, resulting in all 
haematopoietic cells being of donor-type (full chimerism).  Establishment of chimerism is 
accompanied by tolerance of tissues or organs from the bone marrow donor. 101,102  Using 
chimerism for transplant tolerance in recipients without malignancies, however, has 
specific requirements: the conditioning-associated morbidity must be acceptable and the 
ability to mount robust immunological responses to non-donor antigens should be 
preserved.  The state of mixed chimerism, in which haematopoietic cells are a mix of 
donor and recipient, can be established using non-myeloablative conditioning and 
haematopoietic stem cell transplantation (HSCT) and carries a lower risk of graft versus 
host disease (GvHD) and immunocompromise than full chimerism (Figure 2.1).  
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Figure 2.1.  Establishment of haematopoietic mixed chimerism. 
Haematopoietic mixed chimerism can a) be established using non-myeloablative 
conditioning and HSCT.  Following b) bone marrow engraftment, recipients demonstrate a 
mix of donor and host haematopoietic cells. 
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2.2.1 Mouse models 
Peter Medawar and colleagues first demonstrated acquired tolerance of donor 
tissues through establishment of haematopoietic mixed chimerism by injection of bone 
marrow cells into neonatal mice. 99  Subsequently, mixed chimerism and tolerance of fully 
MHC mismatched donor skin grafts were established in adult mice using total body 
irradiation (TBI) followed by reconstitution with donor and recipient bone marrow cells.  
Complete ablation of the recipient haematopoietic compartment using lethal TBI 
prevented rejection of donor bone marrow cells and T cell depletion of donor bone 
marrow cells prevented occurrence of GvHD. 103,104  The toxicity of the conditioning 
regimen, however, precluded clinical application of this approach.   
A less intense protocol to generate mixed chimerism and tolerance involved low-
dose TBI, thymic irradiation, T cell depleting monoclonal antibodies and bone marrow 
transplantation (BMT). 105  Measures to specifically deplete intra-thymic, as well as 
peripheral T cells were identified as important factors for less ablative conditioning. 106  
Further non-myeloablative protocols were developed, in which T cell depletion was 
limited, using co-stimulatory blockade and induction of mixed chimerism facilitated by 
high doses of bone marrow. 107,108  This provided proof-of-principle that strategies to 
induce mixed chimerism could be applied in older individuals with limited thymic output 
and impaired T cell recovery.  
Whether mixed chimerism is established using lethal conditioning or T cell 
depletion and non-myeloablative conditioning, long-term tolerance is maintained by intra-
thymic T cell deletion. 109-111  The depletion or inhibition of recipient T cells before BMT 
allows engraftment of donor haematopoietic stem cells in the recipient bone marrow.  
43 
	
These stem cells give rise to thymic progenitors and antigen presenting cells (APCs) that 
migrate to the thymus and express donor antigen. 111  Newly maturing thymocytes, which 
replenish the peripheral T cell repertoire, then undergo negative selection against donor 
and self.  Following establishment of mixed chimerism and non-responsiveness to donor 
tissues, the infusion of a small number of naïve host-type T cells can break tolerance, 
demonstrating no significant role for peripheral or suppressive mechanisms. 110  In mixed 
chimerism models reliant on co-stimulatory blockade, rather than T cell depletion, 
deletional mechanisms also appear to have a predominant role. 107,108  In addition to intra-
thymic T cell deletion, extra-thymic T cell deletion of alloreactive T cells has been 
observed in this model (Figure 2.2). 107    
Despite these studies, regulatory mechanisms may contribute to maintenance of 
tolerance when low levels of mixed chimerism are established. 112-114  In this setting 
thymic deletion is less complete and alloreactive T cells are controlled in the periphery by 
regulatory pathways, maintaining donor-specific non-responsiveness (Figure 2.2, 2.3).  
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Figure 2.2.  Immunological mechanisms underlying transplant tolerance.   
Regulation versus deletion pathways.  Following HSCT, donor APCs migrate to the 
thymus and present donor antigen.  This leads to intra-thymic deletion of alloreactive T 
cells and selection of donor-specific Tregs.  In the periphery, the presence of donor 
antigen results in extra-thymic T cell deletion and induction of Tregs. 
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2.2.2 Pig models 
Studies of chimerism and transplantation tolerance in swine have used the 
Massachusetts General Hospital (MGH) miniature swine model. 115  In early experiments, 
using conditioning regimens involving lethal irradiation and full donor chimerism, renal 
allograft tolerance was established across haploidentical MHC barriers. 116-118  Similar 
protocols across fully mismatched MHC barriers, however, resulted in poor outcomes due 
to aplastic anaemia and GvHD, with only 1 animal surviving long-term. 119 
As with mouse studies, the development of a non-myeloablative conditioning 
protocol depended on intra-thymic T cell depletion.  This was achieved by development of 
a CD3 immunotoxin, consisting of a CD3-specific monoclonal antibody conjugated with a 
mutant diphtheria toxin, which depleted T cells in peripheral blood, lymph nodes and 
thymus. 120-122  Engraftment of haematopoietic stem cells was further enabled by infusion 
of high-dose peripheral blood stem cells (PBSCs), instead of bone marrow isolated from 
long bones and vertebrae, using apheresis of donor animals that had received porcine stem 
cell factor (pSCF) and interleukin 3 (IL-3) for mobilisation of stem cells. 123,124  After 
iterations to the protocol to prevent side effects, a mild conditioning regimen was 
developed that could induce stable mixed chimerism across haploidentical MHC barriers 
with minimal side effects of PTLD and GvHD. 125,126  This consisted of low-dose (100 
centigray [cGy]) TBI, T cell depletion using CD3 immunotoxin, large doses of PBSC and 
a short course of cyclosporine A (CyA).  Tolerance of transplanted kidneys, hearts and 
lungs was demonstrated in these miniature swine mixed chimeras. 127  
Retrospective analysis of 22 mixed chimeras that underwent conditioning and 
HSCT identified parameters that correlated with establishment of tolerance. 127  Recipient 
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bone marrow engraftment, identified by polymerase chain reaction (PCR) to identify 
donor colony-forming units (CFUs), was the most robust indicator of tolerance.  Other 
important indicators included thymic chimerism and sustained peripheral blood chimerism 
in the myeloid cell lineages. 127      
 
2.2.3 Non-human primate models 
Stable mixed chimerism has been harder to induce in non-human primates (NHP) 
than mouse or miniature swine models.  In addition to TBI, thymic irradiation and T cell 
depletion, splenectomy or CD154 blockade and a short course of CyA is required.  
Splenectomy was performed to prevent acute humoral rejection. 128  This was 
subsequently replaced with CD154 blockade to prevent T cell-B cell interactions, resulting 
in improved chimerism. 129  However, this mixed chimerism is transient since the initial 
establishment of multilineage chimerism is followed by a decline to undetectable levels. 
129-131  Failure to achieve stable mixed chimerism in NHPs was attributable to high 
numbers of memory T cells, which are not present in rodents and are resistant to co-
stimulatory blockade and T cell depletion using monoclonal antibodies. 132-134  
Despite difficulty inducing stable mixed chimerism in NHPs, tolerance of renal 
allografts was observed when the kidneys were transplanted before loss of chimerism. 128-
130  The clinical applicability of this protocol was limited by pre-conditioning of 
recipients, starting 6 days prior to the organ transplant.  Subsequently, a protocol was 
developed in which kidney transplantation is performed under the cover of conventional 
immunosuppression, and conditioning and BMT using cryopreserved cells is performed 
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after 4 months. 134,135  Transient chimerism and transplant tolerance of kidneys and lungs 
was achieved, demonstrating the potential clinical applicability of this “delayed protocol” 
to deceased donor transplantation. 136,137  
The maintenance of renal allograft tolerance despite loss of chimerism suggests 
that peripheral mechanisms are involved in tolerance (Figure 2.2, 2.3).  This is supported 
by the presence of higher levels of FOXP3 mRNA in the renal allografts of tolerant 
animals. 98  
NHP studies have illustrated the role of the transplanted organ itself in the 
establishment of tolerance.  When the transient chimerism protocol was extended to heart 
transplants, allografts were rejected despite prolonged survival. 138  However, when 
kidneys were co-transplanted with hearts, long-term tolerance of both organs was 
observed.  The role of the kidney in maintenance of tolerance was demonstrated by 
rejection of hearts following the removal of kidneys. 139  Current work aims to identify the 
organ-specific factors that result in tolerance versus rejection.    
 
Figure 2.3.  From mouse to man. Contributions of deletion and regulation to organ 
allograft tolerance.  
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2.2.5 Clinical trials 
Clinical transplant tolerance trials have been reported by groups at MGH, Stanford 
and Northwestern University (Table 2.1).  At MGH, an initial trial was reported in a series 
of 7 patients with multiple myeloma and secondary renal failure. 140  Recipients underwent 
non-myeloablative conditioning consisting of cyclophosphamide, T cell depletion with 
ATG, thymic irradiation and a course of CyA. 141-143  Combined kidney and bone marrow 
transplantation was performed across MHC-matched, minor antigen (miHA)-mismatched 
barriers, with some recipients receiving delayed donor lymphocyte infusions in an attempt 
to augment the graft-versus-tumour effect. 144,145  Chimerism was established in all cases, 
varying between transient mixed chimerism, stable mixed chimerism and full chimerism.  
Patients with full chimerism were kept on immunosuppression as prophylaxis for GvHD.  
In the 4 recipients that displayed mixed chimerism (transient or stable), medication was 
withdrawn.  Long-term tolerance of renal allografts was seen in 3 cases, with the longest 
survival exceeding 14 years.  In the fourth patient, progressive multiple myeloma was 
treated with a second HSCT, from the same donor, resulting in full donor chimerism and 
continuation of immunosuppression. 140  Overall, 5 of 7 patients remain alive with deaths 
attributable to recurrence of disease or progressive disease resulting in treatment-related 
acute myeloid leukaemia (AML).  
In a subsequent study at MGH, 10 patients requiring renal transplants entered a 
clinical trial to establish tolerance of the transplanted organ across haploidentical MHC 
barriers. 146  Conditioning consisted of cyclophosphamide, T cell depletion with 
humanised anti-CD2 monoclonal antibody, thymic irradiation, combined kidney and bone 
marrow transplantation and a course of CyA.  The regimen was modified to include pre- 
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and peri-transplant doses of rituximab, after an episode of acute humoral rejection in an 
early patient.  All patients developed transient chimerism, lasting a maximum of 21 days 
and no GvHD was observed. 147  In 9 of 10 patients, “engraftment syndrome” or capillary 
leak syndrome was seen in the second post-operative week, characterised by fever, rash, 
fluid retention and acute kidney injury (AKI). 148,149  This was successfully managed with 
no treatment, steroid boluses or ATG.  Overall, immunosuppression could not be tapered 
in 3 cases, due to acute humoral rejection on post-operative day 10, thrombotic 
microangiopathy at 6 months and cellular rejection 2 months after cessation of 
immunosuppression.  In the remaining 7 patients, immunosuppression was successfully 
discontinued between 8 and 14 months and long-term, rejection-free survival of allografts 
was observed.  The first patient to undergo the protocol has remained tolerant of the renal 
allograft for greater than 10 years.  In one case, chronic humoral rejection was diagnosed 
on biopsy requiring initiation of MMF after 6 years.  In another case, MMF has been 
started for recurrence of membranoproliferative glomerulonephritis but no rejection 
episodes have been observed for greater than 9 years. 147 
Studies in the clinical MGH recipients investigating the underlying mechanisms 
responsible for tolerance suggest that deletional and regulatory pathways are both likely to 
play a role (Figure 2.2, 2.3).  It was initially thought that tolerance induced with transient 
mixed chimerism involved early central deletion followed by peripheral mechanisms 
involving T regulatory cells. 146  Further data indicated that long-term tolerance might be 
maintained by deletion instead, with regulation having a role in the early post-transplant 
period.  Peripheral blood mononuclear cells (PBMC) from tolerant patients displayed non-
responsiveness in mixed lymphocyte reactions (MLR) and cell-mediated lympholysis 
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(CML) assays to donor antigens, with preserved responses to third-party antigens. 146  
Treg-depleted PBMCs taken from recipients greater than a year from transplant 
demonstrated return of responses to donor antigens in some, but not all recipients. 150  The 
inability to consistently demonstrate responses to donor antigens in these assays has been 
explained by presence of deletional tolerance (Figure 2.2). 136  In addition, limiting 
dilution analyses (LDAs) have shown a long-term absence of donor-reactive IL-2 
producing cells or cytotoxic T lymphocyte (CTL) precursors, implicating deletional 
mechanisms. 150  Finally, the loss of donor reactive T cell clones, evolving over time, 
tracked by deep T cell receptor (TCR) sequencing is supportive of tolerance being 
maintained through deletion. 151  
However, higher intragraft levels of FOXP3 in tolerant patients compared with 
conventional transplant patients suggest a role for regulatory pathways as well (Figure 
2.3). 146  Peripheral blood analysis in the early period following conditioning and bone 
marrow transplantation shows Tregs are enriched in the peripheral blood T cell 
population. 141,150  This may be a result of expansion following T cell depletion and early 
induction of thymic Tregs that have been selected on donor APCs that have migrated to 
the thymus (Figure 2.2).152  Consistent with the previous NHP studies, a role for the 
allograft in tolerance induction has also been implicated.  In contrast to the recipients of 
combined kidney and bone marrow transplantation, patients with haematological 
malignancies who received conditioning and haploidentical bone marrow transplantation 
develop strong anti-donor responses following loss of chimerism. 153  The differences in 
these groups suggest the kidney was involved in induction of systemic tolerance.       
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At Stanford, using a conditioning regimen consisting of total lymphoid irradiation, 
ATG, and maintenance CyA and prednisone, 22 subjects received transplants from MHC 
identical donors. 154-156  Transient or stable mixed chimerism was detectable and 16 
patients were successfully withdrawn from immunosuppression.  When the protocol was 
attempted across haploidentical barriers, transient chimerism lasting 2 to 3 months was 
detected in 2 of 5 recipients. 157  Following tapering of immunosuppression, rejection 
episodes were observed and patients were placed on maintenance MMF and CyA.  This 
protocol has now been modified to include CD3+ T cells with the haematopoietic stem 
cell transplants, based on previous studies indicating CD3+ T cells may facilitate the 
engraftment of haematopoietic progenitor cells.  Follow-up of these patients with regards 
to tolerance has not yet been reported, but stable mixed chimerism lasting for 12 months 
has been detectable in some patients. 154  
A third clinical trial has been reported by a group at Northwestern University, with 
outcomes of 19 patients recently published. 158  Recipients underwent a conditioning 
regimen consisting of fludarabine, cyclophosphamide, total body irradiation, HSCT and 
maintenance tacrolimus and MMF.  HSCT was taken by apheresis from living donors who 
varied from 1 of 6 to 6 of 6 mismatched MHC antigens. 159,160  The HSCT product was 
enriched for tolerogenic CD8+, TCR- cells termed facilitator cells (FCs). 159,161,162  The 
major FC subpopulation resemble plasmacytoid dendritic cells but specific details about 
the preparation and mechanism of action have not been fully disclosed.  Eleven patients 
developed full donor chimerism and 1 patient showed stable mixed chimerism.  No cases 
of GvHD were reported.  All of these patients have discontinued maintenance 
immunosuppression with no kidney rejection.  Four patients developed transient mixed 
52 
	
chimerism.  This was associated with kidney rejection upon taper of immunosuppression, 
confirmed by histology. 158  Two patients were being weaned off immunosuppression at 
the time of report and 1 patient had been withdrawn from the study. 
The intensity of the conditioning regimen used in this clinical trial has been 
questioned.  The establishment of full donor chimerism in a number of patients suggests 
that the preparative regimen was myeloablative or recipient haematopoiesis was destroyed 
by donor T cells in the HSCT in a graft versus host reaction.  While patients were 
discharged on day 2 and subsequently managed as an outpatient, the prolonged 
neutropaenia and thrombocytopaenia requiring support with granulocyte colony 
stimulating factor (G-CSF) or transfusions highlights the intensity of the conditioning 
regimen.  The long-term immunocompetence of recipients with full donor chimerism, 
achieved in this protocol, has been questioned. 163,164  Recipients of this protocol also 
developed a number of opportunistic infections, including histoplasmosis, BK virus 
viraemia and herpes zoster.  Two patients have lost their allografts from viral sepsis and 
Klebsiella bacteremia affecting the native polycystic kidney has been observed, although 
it is unclear whether these infections were related to the conditioning regimen. 158  
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Study No. of 
patients 
HLA mismatch Protocol Chimerism Tolerant 
patients 
Pre-transplant Post-transplant 
MGH (1) 7 Matched CY (d-5,-4) 
ATG (d-1) 
TI 700cGy (d-1) 
BMT (d0) 
ATG (d1,3,5) 
CyA (taper) 
Transient, 
mixed 
4/7 
MGH (2) 10 Haploidentical CY (d-5,-4) 
Anti-CD2 MAb (d-1) 
CyA (d-1) 
TI 700cGy (d-1) 
 
Anti-CD2 MAb (d0,1) 
BMT (d0) 
CyA (taper) 
Transient 
mixed 
7/10 
Stanford (1) 6 3/6 – 6/6 TLI 80/100cGy (10 
doses) 
ATG (d0 - 5) 
HSCT (d0) 
CyA (taper) 
Prednisone (taper) 
None/ 
transient 
mixed 
0/6 
Stanford (2) 22 Identical TLI 120cGy (10 doses) ATG (d0 - 5) 
HSCT 
CyA 
Prednisone (d0-10) 
MMF (d0-30) 
CyA (taper) 
Stable/ 
transient 
mixed 
13/22 
Northwestern 19 1/6 – 6/6 Fludarabine (d-4,-3,-2) 
CY (d-3) 
TBI 200cGy (d-1) 
Tacrolimus (d-3,-2,-1) 
MMF (d-3,-3,-1) 
 
FC 
CY (d3) 
Tacrolimus (1yr) 
MMF (6m) 
 
Full stable 9/19 
Table 2.1.  Clinical tolerance trials.  
Tolerant patients are defined as being off immunosuppression for >1year.  CY, 
cyclophosphamide; ATG, anti-thymocyte globulin; TI, thymic irradiation; BMT, bone 
marrow transplantation; CyA, cyclosporine A; HSCT, haematopoietic stem cell 
transplantation; TLI, total lymphoid irradiation; MMF, mycophenolate mofetil; TBI, total 
body irradiation; FC, facilitator cells.  
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2.3 IMPACT OF TOLERANCE ON QUALITY OF LIFE 
 
 Due to the complex conditioning protocols used to establish mixed chimerism, it is 
important to consider whether tolerance protocols achieve improvement in quality-of-life.  
To assess this we performed a survey study of kidney transplant patients on tolerance 
protocols. 165  In comparison with a group of kidney transplant patients receiving 
conventional immunosuppression with matched baseline characteristics, tolerant patients 
experienced significantly less malignancy and infection, and required less medication for 
hypertension, diabetes and dyslipidaemia.  In addition, tolerant patients were less likely to 
experience depression, dyspnea, excessive appetite/thirst, flatulence, joint pain, lack of 
libido, sleep difficulties and vision problems (Table 2.2).  Therefore, in addition to the 
clinical benefits of tolerance, patients experience a significant improvement in quality-of-
life. 
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Table 2.2.  MTSOSD-59R modified transplant symptom occurrence scale among tolerant 
patients and those on conventional immunosuppression.  
(from Madariaga et al. 165) 
 
 This quality of life study, taken together with the clinical outcomes of the 
chimerism-based tolerance studies demonstrates why making tolerance a standard-of-care 
is a long-standing goal of the transplantation community.  In addition to mixed chimerism, 
multiple other approaches are now being pursued in clinical trials including the use of T 
regulatory cells, mesenchymal stem cells and tolerogenic dendritic cells. 166,167  The 
ultimate aim of these efforts is to produce clinical protocols that are fully safe and 
efficacious, cost-effective and require little expertise or time to administer.  While this is 
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an ambitious goal, the initial clinical trials of transplant tolerance using mixed chimerism 
provide a proof-of-concept for further iteration.  Currently only teams with clinical and 
scientific expertise in transplantation tolerance should attempt these clinical protocols.  
Like the VCA community, teams performing tolerance protocols must candidly report 
their short and long-term outcomes, including the complications.  Such an approach is 
essential for the ongoing development and funding of clinical tolerance protocols. 
 
2.4 VCA TOLERANCE 
 
In comparison with solid organ transplantation, VCAs pose unique challenges for 
development of clinically applicable transplant tolerance protocols.  First, the majority of 
VCAs involve skin, which is considered the most antigenic of tissues.  The reliable 
induction of tolerance to this tissue-type is a significant challenge.  Second, VCAs must be 
procured from deceased donors, preventing extensive pre-conditioning of the recipient 
prior to transplantation.  Solutions to this include development of a “day 0” tolerance 
induction protocol where the recipient can be conditioned on the day of VCA harvest.  An 
alternative strategy is the use of protocols where the VCA is performed under the cover of 
conventional immunosuppression with tolerance protocols being performed after a 
delayed time period.  Finally, the requirement for deceased donors has meant that donors 
and recipients, to date, have not been matched for MHC antigens. 168  VCA tolerance 
protocols should, thus, be applicable across MHC disparities.  
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2.4.1 Skin tolerance versus rejection 
Thomas Gibson and Peter Medawar identified the susceptibility of transplanted 
skin to rejection over 70 years ago. 169  Subsequently, the challenge of inducing tolerance 
of skin compared with other tissue types was reported by Joseph Murray’s group in a dog 
model, where tolerance of kidneys but not of skin was achieved when using the same 
protocol. 170  The precise mechanisms that mediate skin tolerance versus rejection still 
remain poorly understood, but several contributing factors are discussed below.  
The phenomenon of skin rejection has been attributed to animal studies largely 
using non-vascularised rather than vascularised grafts.  The beneficial effect of using 
primarily vascularised allografts has been demonstrated in an experiment where non-
vascularised intramuscular implants of kidneys were rejected at an accelerated rate. 171  
However, the antigenicity of skin transplants cannot be explained by differences in blood 
supply alone as small animal studies demonstrate variable survival benefits of skin flaps 
over conventional skin grafts. 172-175  
The observation that long-term chimeric mice rejected skin grafts while 
maintaining tolerance of other organs, termed “split tolerance,” indicated that specific 
antigens found in skin but no other tissues may mediate rejection. 176  While this finding 
has been seen in numerous other mice studies, as well as in dogs and pigs, the 
identification of these skin-specific transplantation antigens has been difficult.  177,178  Skn 
and Epa skin-specific antigens have been found in mice. 179,180  But chimeras that accept 
skin grafts still make antibodies to Skn antigens, suggesting that these might not be 
antigens important in transplantation. 180  Epa antigens do appear to induce T cell reactions 
that can cause skin rejection.  However, these antigens are not truly skin-specific as they 
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are also expressed on fibroblasts, macrophages, haematopoietic cells and in the heart. 181  
It is unlikely that skin-specific antigens alone can account for the vigorous rejection 
response of skin, given that they are minor antigens and should be easier to suppress than 
alloresponses to MHC.  However, immunosuppressive therapies that inhibit rejection of 
MHC-mismatched organ transplants often do not suppress responses to skin from the 
same hosts. 182  
The low threshold for skin rejection has been explained by its intrinsic immune 
function. 181,183  The high content of APCs, including Langerhans cells and dendritic cells, 
may mediate strong rejection responses following transplantation. 183  High expression of 
adhesion ligands and local cytokines promote lymphocyte activation and migration into 
the skin. 184  Lymphocyte activation and proliferation is supported by abundant 
extracellular matrix (ECM) in skin.  By contrast, liver has low levels of ECM and is 
considered among the least susceptible of organs to rejection. 181 
 
2.4.2 Clinical and pre-clinical studies of VCA tolerance  
No clinical trials for tolerance of VCAs have been performed to date.  However, a 
protocol to minimise, rather than stop, immunosuppression has been attempted.  Patients 
were treated with T cell depletion and steroids at the time of hand transplantation and 
subsequently maintained on tacrolimus monotherapy. 47  On day 14 unmodified bone 
marrow cells, taken and cryopreserved from the vertebral bodies of donors, was given by 
intravenous infusion.  No detectable chimerism was observed.  Doses of tacrolimus were 
gradually tapered over the first year to trough levels of 4-12ng/ml.  This level of 
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immunosuppression is significantly lower than in other VCA recipients.  Tolerance was 
not seen as patients experienced acute rejection episodes of the VCA, which were treated 
with adjustment of tacrolimus doses, steroid boluses or topical immunosuppression.  
Intimal hyperplasia was detected under high-resolution ultrasound in 1 patient. 47 
Mixed chimerism remains the only strategy to have demonstrated tolerance of 
allogeneic VCAs in large animal models.  Tolerance of miniature swine limb allografts, 
containing VBM and muscle, but no skin, was achieved in MHC-matched, miHA-
mismatched settings using a 12-day course of CyA. 185,186  Low level (<5%) mixed 
chimerism, achieved from donor cells in the VBM, was seen for a maximum of 56 days 
post-operatively. 187  When the same strategy was applied to limb transplants containing a 
vascularised skin segment, tolerance to all components except the skin was achieved. 188  
In a subsequent study using a clinically-relevant conditioning regimen of T cell depletion, 
HSCT and 30 days of CyA in MGH miniature swine, limb transplants were performed 
across haploidentical and full mismatch MHC barriers. 189  Recipient animals displayed 
either transient levels of mixed chimerism or no chimerism.  Long-term acceptance of the 
musculoskeletal components of VCAs was achieved, but the skin component was rejected.  
Following conditioning and HSCT, PBMC from recipient animals displayed donor-
specific hyporesponsiveness in MLR and CML assays.   
Tolerance of all components of allogeneic VCAs, including the skin, has been 
achieved in large animals through the induction of stable mixed chimerism.  In a canine 
model stable chimerism and tolerance of VCAs was established across MHC-matched, 
miHA-mismatched disparities with 200cGy TBI, BMT and a 35-day course of 
maintenance immunosuppression. 190  Tolerance of VCAs has recently been achieved 
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across haploidentical MHC barriers in the MGH miniature swine model. 191  Recipients 
underwent a conditioning regimen consisting of T cell depletion, TBI, HSCT and 45 days 
of CyA.  VCAs consisting of a primarily vascularised skin paddle and were performed 
from donor animals after 100 days or at the time of HSCT.  Stable mixed chimerism was 
established and tolerance of all VCA components, including the skin, was observed with 
no clinical or histological signs of rejection at any point.  Donor-specific non-
responsiveness was demonstrated on CML and MLR, with no in vitro evidence of 
rejection found in CD25+ depletion assays. 191 
In an alternative strategy, establishment of VCA tolerance using 
immunomodulatory strategies applicable to renal transplantation was attempted.  
Tolerance of renal allografts can be uniformly induced in miniature swine across MHC 
class I or full MHC mismatches using a 12-day course of high-dose calcineurin inhibition. 
192,193  Once tolerant, these animals accept another MHC-matched kidney without further 
immunosuppression. 192  The mechanism underlying long-term acceptance involves 
systemic immunomodulation, evidenced by in vitro studies demonstrating the necessary 
presence of a regulatory cell population. 194,195  The same regimen was unable to prolong 
the survival of heart allografts. 196,197  However, when hearts were co-transplanted with 
kidneys, tolerance of both organs was achieved. 196,197  In order to investigate whether this 
kidney-induced tolerance (KIT) could be extended to VCAs, allografts consisting of 
primarily vascularised gracilis muscle plus overlying skin were placed on animals tolerant 
of MHC class I disparate kidneys. 198  VCAs were MHC-matched to the kidney donor.  
The skin was rejected in 5 out of 6 cases, with tolerance of all other components 
established.  
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2.5 EFFECT OF MHC ANTIGEN SHARING IN TOLERANCE  
 
Studies of solid organ transplantation have demonstrated that MHC antigen 
sharing between donors and recipients affects transplant tolerance.  In initial experiments 
using MGH miniature swine, renal allografts were performed without the use of 
immunosuppression, where donors and recipients were MHC matched.  In approximately 
a third of the cases, the allografts were tolerant. 182,199  In MHC mismatched combinations, 
class I-matched, 1-haplotype class II-mismatched kidney transplants all rejected.  
However, class II-matched, 1-haplotype class I-mismatched allografts were spontaneously 
tolerant at the same incidence as MHC matched transplants. 182,200  Spontaneous acceptors 
experienced acute rejection crises in the initial post-operative weeks, which resolved 
without treatment. 182  Cytotoxic immunoglobulin (Ig) M antibody reactive against class I 
antigens were detectable during acute rejection episodes.  The absence of IgG antibodies 
indicated that the switch from IgM to IgG, which required T cell help, had not occurred.  
Taken together, these data indicate that class I antigens were detected but tolerised. 182  
Subsequent studies aimed to actively induce transplant tolerance of renal allografts 
across MHC barriers, using a short course of high-dose CyA.  Across 2-haplotype class I-
mismatched, class II-matched barriers tolerance of allografts was achieved in all cases. 192  
However, in 2-haplotype class II-mismatched, class I-matched combinations, tolerance 
was harder to establish. 201  Across 2-haplotype class I plus 2-haplotype class II (full MHC 
mismatch) settings, rejection was consistently seen. 192  
These early studies demonstrated that the sharing of MHC class II antigens 
between donors and recipients could favor induction of tolerance. 202  Subsequently, using 
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a gene therapy approach, a single DQ allele was transferred to the bone marrow cells of 
recipient swine.  A subsequent renal allograft from donor animals expressing the same DQ 
allele, but otherwise mismatched at MHC class I and II antigens, was tolerant.  The linked 
tolerance of the disparate MHC antigens mediated by the transfer of a single class II 
antigen suggested regulatory pathways had mediated tolerance.  
In pre-clinical, large animal studies VCA tolerance has been established across 
haploidentical MHC barriers, in which there is partial sharing of antigens at MHC class I 
and class II between donors and recipients.  Given that clinical VCAs have used deceased 
donors without MHC antigen matching, transplants have been performed across varying 
disparities including full MHC mismatches.  Therefore determining the role of MHC 
antigen matching in VCA tolerance will be critical in establishing a clinically feasible 
tolerance protocol.  
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3. HYPOTHESIS AND AIMS 
	
I hypothesized that MHC antigen matching between donors and recipients would 
influence VCA tolerance.  In this study, I examined the effect of MHC class I and class II 
sharing on VCA tolerance in the pre-clinical MGH miniature swine model. 
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MATERIALS AND METHODS 
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MATERIALS 
4.1 ANIMALS  
	
4.1.1 MGH Miniature Swine  
Background 
Development of the MGH miniature swine model started in 1972 due to the 
requirement for a genetically defined, easily available large animal model for studies in 
transplantation biology. 203  In comparison with other large animal species, miniature 
swine have several advantages as a large animal model. 203,204  Firstly, miniature swine 
resemble humans in size and do not generally exceed 250lbs.  Secondly, the physiology of 
miniature swine, including cardiovascular, respiratory and digestive systems are similar to 
humans.  Thirdly, the breeding characteristics are compatible for usage as an experimental 
model.  Miniature swine are sexually mature at 4 to 6 months of age, have an oestrous 
cycle every 3 weeks, have a gestation period of 3 months and 3 days and have litter sizes 
between 4 and 10 offspring.  MGH miniature swine were initially developed at the 
National Institutes of Health (NIH) by following a breeding programme in which 3 
distinct herds of animals were produced, each homozygous for alleles at the major 
histocompatibility locus. 
 
Breeding Programme  
 Two breeder animals were chosen from separate herds of miniature swine to 
ensure diversity of the MHC at the start of the breeding programme. 203  Swine have A and 
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O blood groups.  In order to facilitate the development of a transplantation model, both 
initial breeder animals were chosen to be O negative blood group.  Prior to starting 
breeding, the original parents were reciprocally immunized using skin grafts and 
leukocyte injections to produce lymphocytotoxic sera.  Following reciprocal skin grafting, 
cytotoxic antibodies were detected in the serum of both animals after 2 weeks and 
subsequently remained elevated.  These antibody levels were boosted with reciprocal 
intramuscular lymphocyte injections.  Antisera was raised from the centrifugation of 
blood-draws and stored.  Based on the assumption that the initial animals chosen for 
breeding differed at MHC alleles, the genotypes at the MHC were assigned as AB for pig 
1 and CD for pig 2 (Figure 4.1).  The immunization of pig 1 with skin grafts and 
lymphocytes from pig 2 should, thus, produce anti-C and anti-D antibodies.  Similarly, pig 
2 should produce anti-A and anti-B antibodies.  The inheritance of the MHC alleles in the 
offspring can then be determined based on selective absorption of cytotoxicity.  For 
example, the anti-C antibodies of immunized parent AB serum (containing cytotoxic anti-
C and anti-D antibodies) can be absorbed with peripheral lymphocytes from an AC 
offspring animal.  The remaining anti-D antibodies in the immunized AB serum will 
demonstrate cytotoxicity to lymphocytes from AD and BD offspring animals, but not AC 
or BC animals (Figure 4.1).  When this was performed, a B haplotype was not identified in 
the first generation.  This may have been due to pig 1 being a homozygote at the MHC 
(AA) or that he was a heterozygote but only the A haplotype was transmitted to his 
offspring by chance.  The death of pig 1 prevented further breeding and studies with this 
animal.  Using serological typing to characterize the MHC alleles of each generation, by 
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the third generation of breeding 3 lines of pig, each homozygous at the MHC, were 
produced. 203   
 
 
Figure 4.1.  Breeding of the MGH miniature swine model.  
Analysis of first generation MGH miniature swine progeny using cytotoxic anti-sera. 
 
(from Sachs et al. 203) 
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These initial lines were homozygous at only the MHC, while minor antigens were 
not fixed (Figure 4.1).  Breeding was continued to maintain these minor antigen variances 
within the lines to maintain relevance to transplantation within human families (Human 
Leukocyte Antigen [HLA] identical siblings).  To develop a syngeneic line with 
homozygosity at all genetic loci, the DD line was chosen for brother-sister mating over 
multiple generations. 205  By the seventh generation, skin and heart transplantation 
performed between inbred DD animals were accepted long-term without 
immunosuppression.  The inbreeding programme within this line has now reached the 
eleventh generation, with co-ancestry analysis revealing a greater than 95% 
histocompatibility for all genetic loci.  
Currently the 3 homozygous haplotypes (SLAaa, SLAcc and SLAdd) and 5 
heterozygous lines comprising combinations of class I and class II loci from the 3 
homozygous lines are maintained (Figure 4.2).  The availability of these lines provides a 
unique large animal model for the research aims of the present study, in which VCAs can 
be reproducibly transplanted across mismatches for MHC antigens.    
MGH miniature swine are a specific pathogen-free herd (free of pseudorabies, 
porcine reproductive and respiratory syndrome, transmissible gastroenteritis, viruses and 
brucellosis).  Animals are bred at a specific facility in Grafton, Massachusetts.  Overall 
breeding patterns are designed to preserve lines.  Approximately 500 pigs are maintained 
at the breeding facility at one time.  Animals for upcoming experiments are transferred to 
the large animal facility at the TBRC.  This facility is accredited by the Association for 
Assessment and Accreditation of Laboratory Animals Care (AAALAC).  Animals 
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undergoing HSCT are housed in conventional steel cages with high efficiency particulate 
arrestance (HEPA) filters. 
 
 
 
Figure 4.2.  Characteristics of MGH miniature swine.  
a) Haplotypes of MGH miniature swine.  Minor antigen differences are maintained.  b) 
The size (approximately 200 lbs when fully grown) and breeding characteristics of this 
animal model make it suitable for large animal transplantation studies. 
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The Swine Leukocyte Antigen Complex  
 The swine leukocyte antigen has been mapped to chromosome 7. 206,207  There are 
7 classical class I genes. The functional class I genes (SLA -1, SLA-2 and SLA-3) code 
for 45kDa transmembrane glycoproteins (consisting of α1, α2 and α3 domains) that bind 
covalently to a 12kDa β2-microglobulin. 208  Similar to HLA class I molecules, the α1 and 
α2 domains form a peptide-binding groove which can present peptides to CD8+ cytotoxic 
T cells and interact with natural killer (NK) cells. 208,209  The heterodimeric SLA class I 
proteins are constitutively expressed on the cell surface of almost all nucleated cells. 208  
 Consistent with HLA class II antigens, SLA class II antigens (SLA-DR and SLA-
DQ) are heterodimers, consisting of a 34kDa α protein bound non-covalently to a 29kDa β 
chain. 208  The α1 and β1 domains form the peptide-binding groove.  The SLA class II 
antigens are found on the surface of the professional antigen presenting cells, including 
macrophages, B cells and dendritic cells. 210-212  Unlike humans, T cells express SLA class 
II antigens. 213  SLA class II antigens serve to present exogenous peptides to CD4+ T 
helper cells. 208  
 The SLA genes are highly polymorphic, but less so than HLA genes.  A total of 
116 SLA class I alleles and 167 SLA class II alleles have been discovered to date. 214,215  
By comparison over 2000 class I alleles and 900 class II alleles have been identified in the 
HLA system.               
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4.1.2 Yorkshire swine 
Yorkshire swine are a genetically different herd from MGH miniature swine.  The 
Yorkshire swine used in this study were outbred, providing an immunologically distinct 
source of swine antigens for use in in vitro studies.   
 
4.1.3 Ethical approval for animal use 
All animal care and procedures were approved by the MGH Institutional Animal 
Care and Use Committee and conducted in compliance with the “Guide for the Care and 
Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources, 
National Research Council, and published by the National Academy Press, Washington 
D.C., USA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
	
4.2 ANTIBODIES  
 
The following list (Table 4.1) of swine-specific antibodies were used in this study: 
 
Antibody Clone Species Colour 
CD3 898-12-6-15 rat FITC/BIO 
CD4 74-12-4 mouse FITC/BIO/PE 
CD8 76-2-11 mouse FITC/BIO/PE 
CD16 G7 mouse FITC/BIO 
CD21 B-ly-4 mouse PE 
CD25 231-382 mouse FITC/BIO 
CD45RA Fg2F9 mouse FITC/BIO/PE 
CD172 74-22-15 mouse FITC/BIO/PE 
PAA 1038 H-10-9 mouse FITC/BIO 
Table 4.1.  List of antibodies used to detect cell lineages and chimerism.
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4.3 DRUGS 
 
	
4.3.1. Cyclosporine A 
CyA was made in a sterile hood with the lights off.  Powdered CyA was provided 
by Novartis Pharmaceuticals.  Cremaphor was added to a 2L sterile glass beaker with a 
magnetic stirring bar.  This was placed on top of a stirring plate.  CyA powder was added 
to the Cremaphor while stirring, to prevent precipitation.  Ethanol and sterile water were 
added with aseptic technique to the CyA solution.  The beaker was covered with 
aluminium foil to prevent light penetration and left overnight to stir.  The CyA mixture, at 
50mg/ml, was aliquoted into 50ml glass bottles and wrapped in aluminium foil.  These 
bottles were stored at room temperature.   
 
4.3.2. Tacrolimus 
Powdered tacrolimus (Haorui Pharma-Chem Inc, Irvine, CA) at a dose of 1g was 
dissolved in 160ml of 100% ethanol and 40ml of Cremaphor in a sterile hood.  This 
5mg/ml solution was mixed until clear and then aliquoted into 5ml vials.  The aliquots 
were stored at room temperature.  
 
 
 
74 
	
4.3.3. CD3 Immunotoxin 
 Anti-CD3 immunotoxins are effective reagents in the transient depletion of T cells.  
A diphtheria toxin based anti-porcine CD3 recombinant immunotoxin was developed at 
the Transplantation Biology Research Center, in the Recombinant Protein Expression and 
Purification Core Facility. 216  A truncated diphtheria toxin DT390 (the protein is truncated 
at amino acid residue 390) was fused with 2 tandem single chain variable fragments 
derived from the anti-porcine CD3 monoclonal antibody 898H2-6-15.  This bivalent 
fusion toxin was expressed in the yeast Pichia pastoris, which is diphtheria toxin resistant, 
under the control of the alcohol oxidase promoter.  The secreted recombinant CD3 
immunotoxin was purified in a 2-step chromatography protocol. 216  
 
4.3.4. Porcine stem cell factor 
 Recombinant pSCF, acquired from BioTransplant, Boston, Massachusetts, USA, 
was used for cytokine mobilization of donor animals for PBSC donation.  
 
4.3.5. Interleukin 3 
 IL3 was used for cytokine mobilization of donor animals for PBSC donation.  
Recombinant IL3 was expressed using the yeast Pichia pastoris and subsequently purified 
in the Recombinant Protein Expression and Purification Core Facility at the 
Transplantation Biology Research Center. 217 
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4.4 MEDIA 
	
4.4.1 MLR Media 
MLR media consisted of RPMI 1640 (Life Technologies) supplemented with 6% 
fetal pig serum (FPS, Sigma; St. Louis, MO, USA), 100U/ml penicillin (GIBCO-
Invitrogen Corporation; Carlsbad, CA, USA), 135ug/ml streptomycin (GIBCO-Invitrogen 
Corporation), 50ug/ml gentamicin (GIBCO-Invitrogen Corporation), 10mmol/L 4-2-
hydroxyethyl-1-piperazine-ethanesulfonic acid (HEPES; Fisher Scientific, Pittsburgh, 
PA), 2mmol/L L-glutamine (Life Technologies), 1mmol/L sodium pyruvate 
(BioWhittaker–Cambrex; East Rutherford, NJ, USA), nonessential amino acids 
(BioWhittaker–Cambrex) and 5 x 10-5mmol/L β2-mercaptoethanol (Sigma Chemical). 
 
4.4.2. CML Media 
CML media consisted of RPMI-1640 supplemented with 6% fetal bovine serum 
(FBS, Sigma Chemical Co, St Louis, MO), 100U/ml penicillin, 135ug/ml streptomycin, 
50ug/ml gentamicin, 10mmol/L HEPES, 2mmol/L L -glutamine, 1mmol/L sodium 
pyruvate, nonessential amino acids, and 5 × 10–5mmol/L β2-mercaptoethanol.  The 
takedown media for use in the effector phase of the CML assay was performed with Basal 
Medium Eagle (Gibco BRL) supplemented with 6% fetal bovine serum (Sigma 
Chemical). 
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4.4.3. CFU Media 
CFU media consisted of 6% fetal bovine serum, 11ng/ml recombinant porcine 
stem cell factor, 0.85ng/ml recombinant porcine IL-3, 2ng/ml recombinant porcine GM-
CSF, 0.85U/ml recombinant human EPO, Isocove’s Modified Dulbecco’s Medium 
(IDMD, Thermofisher) and Methocult H4230 (StemCell Technology).  CFU media was 
divided into 3ml aliquots in 15ml snap cap tubes and stored in a -20°C freezer until use.    
 
4.5 RADIOACTIVE ISOTOPES 
	
 Chromium-51 (51Cr), 1.0mCi/ml, specific activity 400-1200Ci/g (Perkin Elmer 
cat# NEZ030S005MC) was used in CML in vitro assays.  Tritiated thymidine (3H) was 
used in MLR in vitro assays. 
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METHODS 
4.6 EXPERIMENTAL MODELS   
 
4.6.1 Mixed chimerism model 
Animals 
Donor animals were chosen from the MGH miniature swine herd to be 
approximately 50kgs and 8-10 months old.  Animals of this size and age were chosen to 
allow mobilization of adequate numbers of PBSCs, while limiting the experimental costs 
required for cytokines.   
Recipient animals were chosen to be 8-15kgs and 8-12 weeks old.  Two recipient 
animals were chosen for each donor animal.  The size and the weight of the animals were 
selected to achieve HSCT using the target number of PBSCs. 
In the first group, SLAgg (class Ic/IId) donors and SLAdd (class Id/IId) recipients 
were selected to achieve a 2-haplotype, MHC class I mismatch between donors and 
recipients.  In the second group, SLAgg (class Ic/IId) donors and SLAcc (class Ic/IIc) 
recipients were selected to achieve a 2-haplotype, MHC class II mismatch (Figure 4.2).  
Pig allelic antigen (PAA), a non-histocompatability antigen, was mismatched between 
donor and recipient animals to allow monitoring of origin of haematopoietic cell lineages 
following HSCT.218  
All animals were brought from the farm to the laboratory housing facility at least 1 
week prior to the start of the conditioning protocol, to allow acclimatisation, insertion of 
central lines and completion of pre-conditioning in vitro assays.   
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Conditioning protocols 
Recipient animals underwent a non-myeloablative conditioning regimen to 
establish stable mixed chimerism. 126  Day 0 of the protocol was defined as the first day of 
HSCT.  Recipient animals underwent transient, partial T cell depletion with a CD3-
immunotoxin (recombinant CD3-IT, pCD3-DT390 50ug/kg intravenously twice daily 
from day -4 to -1).  This dose and timing for the CD3-immunotoxin was based on previous 
studies in miniature swine to permit adequate T cell depletion for induction of chimerism, 
while limiting the potential side effect of neurotoxicity.  Prior to administration, animals 
were pre-treated with 2-4mg/kg diphenhydramine (diluted in 10mls of 1X PBS) 
administered by intravenous infusion over 5 minutes.  Sterile 1X PBS (5mls) was 
administered intravenously immediately before and after giving the CD3-immunotoxin.   
On day-2, recipient animals underwent 100cGy TBI. 216  Animals were sedated 
with 0.15mg/kg intravenous telazol and placed in plexiglass cages.  Midline TBI was 
administered from a cobalt 60 irradiator.  CyA was given intravenously, starting from day 
-2 and continued to day 30 with a trough level aimed at 400-800ng/ml.  CyA was 
administered at an initial dose of 15mg/kg by twice daily intravenous infusion.  The dose 
was adjusted depending on the trough drug levels. After day 30, the dose of CyA was 
tapered to discontinuation by day 45 (Figure 4.3).  
Donor animals received porcine IL-3 and pSCF for mobilisation of PBSCs.  Both 
cytokines are dosed at 100ug/kg to 30kgs and 50ug/kg thereafter.  Prior to administration 
of cytokines, donor animals are given 2-4mg/kg diphenhydramine (diluted in 10mls 
normal saline) by intravenous infusion over 5 minutes.  The donor animals were then 
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sedated by intravenous administration of 2mg/kg ketamine diluted in 10mls of normal 
saline.  Central lines are flushed and capped and the animal is maintained on inhaled 
isofluorane for further sedation, if required.   Cytokines are injected intramuscularly into 
the muscle of the posterior neck using a 22G needle.  The animal is subsequently 
monitored during its recovery.  Cytokine injections are repeated daily for 7 days.  After 
administering 4 doses of cytokines (day 0 of the protocol) collection of PBSCs was 
commenced via leukapheresis using a COBE Spectra Apheresis System (Lakewood, 
Colorado, USA).  The target number of mobilised haematopoietic stem cells to be 
collected was 15×109 cells/kg recipient weight.  This was administered intravenously to 
recipient animals as the cells were collected on days 0, 1 and 2 of the protocol.  VCA 
transplants, consisting of primarily vascularised skin flaps, were performed on day 3. 
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Figure 4.3.  Non-myeloablative conditioning regimen to establish stable mixed 
chimerism.  
Animals were conditioned with CD3-IT for transient T cell depletion, 100cGy TBI and a 
45-day course of CyA.  HSCT was performed on days 0-2.  VCAs were performed on day 
3.
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4.6.2 Immunomodulation model  
A short course of high-dose calcineurin inhibition can induce tolerance of renal 
allografts transplanted across MHC class I or full MHC barriers.  Tolerance in this model 
is dependent on regulatory pathways mediated by the presence of the kidney and can be 
extended to co-transplanted hearts. 
In the first group, to generate an MHC disparity across a haploidentical barrier, 
SLAac (class Iac/IIac) animals received heart and kidney transplants from SLAad (class 
Iad/IIad) donors (Figure 4.2) with 12 days of tacrolimus, followed after 100 days with a 
donor MHC-matched SLAad (class Iad/IIad)  myocutaneous VCA transplant without further 
immunosuppression.  In the second group, to generate an MHC disparity across a full 
MHC mismatch, SLAcc (class Icc/IIcc) animals received heart and kidney transplants from 
SLAdd (class Idd/IIdd) donors (Figure 4.2) with 12 days of tacrolimus, followed after 100 
days with a donor-matched SLAdd (class Idd/IIdd) myocutaneous VCA transplant without 
further immunosuppression.       
Tacrolimus (Haorui Pharma-Chem Inc., Irvine, CA) was mixed and administered 
as an intravenous suspension according to the specifications of the manufacturer.  
Tacrolimus was given as a continuous infusion at a dose of 0.08-0.20mg/kg (adjusted to 
maintain a whole blood level of 30-50ng/ml) for 12 consecutive days, starting on the day 
of heart and kidney transplantation (day 0).  	
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4.7 SURGICAL PROCEDURES   
 
4.7.1 Fasciocutaneous VCA transplantation  
Approximately 1 hour prior to operations, animals were sedated using Telazol 
(1.4mg/kg IM or IV), glycopyrolate (0.01mg/kg IM or IV) and xylazine (2mg/kg IM or 
IV).  Prior to surgery, animals were intubated via endotracheal tube and maintained under 
inhalational anaesthesia using isoflurane.   
Fasciocutaneous VCAs were used in the chimerism model for consistency with 
previous experiments of VCA tolerance in mixed chimeras across haploidentical MHC 
barriers. 191,219  Donor miniature swine animals were anaesthetised, placed supine on the 
operating table and prepped for surgery.  A paddle of skin measuring approximately 
100cm2 was elevated on the medial aspect of the leg, along with underlying subcutaneous 
tissue and fascia.  The saphenous vessels were identified and preserved as the vascular 
pedicle.  The saphenous vessels were carefully dissected to their junction and 2cm of the 
femoral vessels were harvested for the vascular anastomosis. 219  On division of the 
vascular pedicle, the femoral artery was flushed with 100U/ml heparinised saline (Figure 
4.4).  
The recipient animals were prepared using a 5cm paramedian incision in the neck 
to expose the right common carotid artery and right internal jugular vein.  Vascular 
anastomoses between the carotid artery/jugular vein and femoral vessels were performed 
under microscopic magnification.  
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Figure 4.4.  Preparation of a fasciocutaneous VCA.  
a) VCAs consisting of a primarily vascularised paddle of skin and underlying fascia were 
marked out using the saphenous vessels; b) the VCA was raised and the vascular pedicle 
consisting of the femoral artery and vein were dissected.  The vascular pedicle was 
anastomosed to the recipient common carotid artery and internal jugular vein and c) inset 
into the neck. 
 
4.7.2 Myocutaneous VCA transplantation 
Myocutaneous VCAs were used in the immunomodulation model for consistency 
with previous experiments of VCA tolerance using immunomodulatory pathways across 
MHC class I barriers. 198  The saphenous artery was palpated on the medial aspect of the 
leg and a cutaneous skin paddle was marked around this axis.  The skin island was isolated 
and sutured to the subcutaneous tissue to avoid avulsion of the perforating vessels.  The 
underlying gracilis muscle was isolated with perforating vessels from the femoral artery 
and vein.  The femoral vessels were identified and dissected and the flap was isolated 
(Figure 4.5).  End-to-end anastomosis was performed to the recipient common carotid 
artery and internal jugular vein.  The VCA was inset into the cervical region. 220  
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Figure 4.5.  Myocutaneous VCAs. 
VCAs consisting of primarily vascularised skin, fascia and underlying gracilis muscle 
were used in the immunomodulation model.  The vascular pedicle included the femoral 
artery and vein.  Perforating branches from the femoral artery were preserved to supply 
the gracilis muscle.  
 
4.7.3 Heart and kidney transplantation 
The recipients underwent bilateral nephrectomy.  Kidney transplantation was 
performed by end-to-side anastomoses of the renal artery to the aorta, renal vein to the 
inferior vena cava, and ureter to the bladder.  Heart transplantation was performed by end-
to-side anastomoses of the donor aorta to the recipient aorta and pulmonary artery to the 
inferior vena cava.  The heart was placed at least 1cm caudad to the kidney.  
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4.7.4 Central line insertion 
Indwelling silastic central venous catheters were placed surgically into the external 
or internal jugular veins.  The length of catheters allowed the ends to lie within the 
superior vena cava.  Catheters were tunneled to exit the skin on the dorsum of the neck.  
The catheters facilitated immunosuppression administration and frequent blood sampling 
for in vitro assays and for monitoring of peripheral blood chimerism, whole blood 
tacrolimus or CyA levels and blood tests.  Lines were flushed twice daily with 10ml of 
normal saline and 3ml of 100U/mL heparinized saline to prevent clots from forming. 
 
4.7.5 Thymus and bone marrow biopsy 
 Thymus and bone marrow biopsy specimens were taken pre-transplant and on day 
50, 100 and 150 post-transplant via a 5cm incision in the neck and sternum of recipient 
animals.  Thymus specimens were assessed for chimerism while bone marrow samples 
were used to determine engraftment of donor cells in recipient bone marrow.  
 
4.7.6 Split-thickness skin grafting and monitoring 
Split-thickness skin grafts were used to assess the robustness of tolerance in 
chimeric animals.  Split-thickness skin grafts from donor animals and donor MHC-
matched, miHA-mismatched animals were placed on recipient animals.  These were 
harvested using an air dermatome at a thickness of 0.022 inch.  Skin grafts were 
approximately 3cm × 5cm and stored in saline.  Skin grafts were then wrapped in sterile 
nylon meshes before adding skin freezing medium, which was made by 1:1 ratio of 
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cryoprotective media (Lanza BioWhittaker) and fetal porcine serum filtered through a 
0.45uM filter unit.  Skin grafts were frozen using a liquid nitrogen freezer.  Before use, 
skin grafts were thawed in a 37°C water bath and transferred to MLR media.  
In order to place skin grafts on chimeric animals, wound defects were made using 
2 passes of an air dermatome set to 0.022 inch thickness.  Punctate bleeding of the wound 
beds was controlled with pressure or topical epinephrine.  Fenestrations were made in the 
skin grafts using a 10 blade.  Skin grafts were secured with nylon sutures and dressed with 
pressure dressings post-operatively to aid graft take.  Dressings were removed after a 
week and skin grafts were monitored daily by clinical inspection for warmth, color and 
crusting.  Skin graft loss was defined clinically when less than 10% of the total skin in the 
graft was viable.  
 
4.8 REJECTION MONITORING   
	
Post-operatively, VCAs were monitored daily for clinical signs of rejection, 
identified by redness, swelling and skin crusting.  Tolerance was defined as rejection-free 
VCA survival for 100 days off immunosuppression.  VCA and host skin biopsies were 
performed at week 2, week 4, day 50, day 150, day 200 and day 250 post-transplant. 
Biopsied tissue was fixed in formalin, stained with haematoxylin and eosin (H&E) and 
analysed under light microscopy.  Scoring of rejection was performed without knowledge 
of the clinical status of the VCA based on the Banff criteria. 221  Immunohistochemistry 
was performed on formalin-fixed, paraffin embedded specimens using antibodies for CD3 
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(rabbit anti-human CD3 [DAKO, Carpinteria, CA] and FoxP3 (rat anti-FoxP3 
[eBioscience]).  
Kidney function was monitored by serial serum creatinine levels.  Renal allograft 
rejection was defined as sustained rise in serum creatinine to >884umol/L and/or uraemia.  
Heart function was monitored by daily palpation and electrocardiogram (ECG) using the 
AliveCor Veterinary Heart Monitor (AliveCor, Inc., San Francisco, CA).  Cardiac 
allograft rejection was defined by either loss of a ventricular impulse on palpation and/or 
QRS-wave amplitude of less than 0.3 millivolts and/or the lack of ventricular contraction 
on echocardiography. 222 
Core needle biopsies were performed on cardiac allografts.  Wedge biopsies were 
performed on kidney allografts.  Kidney biopsies were taken at the same time as the heart 
samples.  Tissue was fixed in formalin and embedded in paraffin for routine light 
microscopy (H&E).  Scoring of rejection was performed without knowledge of the 
functional status of the graft based on the International Society for Heart and Lung 
Transplantation System for hearts and the current Banff consensus criteria for kidney 
allografts. 223  
 
4.9 CHIMERISM MONITORING   
	
4.9.1 Whole blood FACS 
Chimerism (percentage of detectable donor cells) was assessed in the peripheral 
blood by flow cytometry twice weekly during the first week following HSCT and weekly 
thereafter.  Flow cytometry uses fluorescently labeled antibodies to detect specific cell 
surface proteins.  Blood draws (5ml) were taken from animals via indwelling central lines 
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for assessment of chimerism and stored in heparinised tubes.  Whole blood was aliquoted 
(100ul) into each FACS tube.  FACS media (2ml) was added to each tube and all tubes 
were centrifuged at 1200 rpm for 5 minutes at room temperature.  The supernatant was 
discarded and the tubes were gently vortexed.  Unconjugated antibody (10ul) was added to 
each tube.  The following swine specific antibodies were used: CD3, CD4, CD8α, CD172, 
CD16, CD25 and PAA.  The tubes were gently vortexed and incubated for 30 minutes at 
room temperature in the dark.  FACS media (2ml) was added to each tube.  Samples were 
subsequently vortexed and centrifuged at 1200 rpm for 5 minutes at room temperature.  
The supernatant was discarded, the tubes vortexed and necessary secondary antibodies 
(10ul) were added.  This was followed by vortexing and incubating for 15-30 minutes at 
room temperature in the dark.  FACS Lysing Buffer (2ml) were added to each tube.  This 
acts to lyse the red cells and fix the peripheral blood mononuclear cells.  The supernatant 
is then discarded, the tubes were vortexed and washed twice with 2 ml of FACS buffer. 
Samples were eventually re-suspended in 0.4ml of FACS media and acquired on a 
FACSCalibur (Becton Dickinson, USA).  Data were analysed in FlowJo (TreeStar Inc., 
USA).   
 
4.9.2 Tissue FACS 
Tissue chimerism in thymic biopsy specimens was also determined using flow 
cytometry, following preparation of single cell suspensions.  Cells were re-suspended in 
FACS media at 1×107 cells/ml.  100ul of cell solution is aliquoted per FACS tube.  10ul of 
antibody is added to each tube and samples are incubated for 30 minutes at 4°C.  2ml of 
FACS media was then added per tube and samples were centrifuged at 1200 rpm for 5 
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minutes at 4°C.  The supernatant was discarded and the tubes were washed with FACS 
media and centrifuged again.  If an unconjugated primary antibody was used, an 
appropriate secondary antibody was added.  This was followed by a 30 minute incubation 
at  4°C and 2 washes with FACS media, as described previously.  Samples were 
eventually re-suspended in 0.4ml of FACS media and acquired on a FACSCalibur. 
 
4.9.3 Colony Forming Unit Assays 
Bone marrow engraftment of donor cells was determined by CFU assay.  Recipient 
bone marrow specimens taken pre-transplant and on day 50, 100 and 150 were placed into 
a tissue culture dish and cut into slices using sterile forceps and scissors.  Using the flat 
end of a sterile 10ml syringe plunger, the bone marrow tissue was crushed.  The cell 
suspension was washed with Hanks Balanced Salt Solution (HBSS) and filtered through a 
40uM filter into a 50ml conical flask.  The cell suspension was centrifuged at 1400 rpm 
for 10 minutes.  The pellet was inspected and the supernatant discarded.  The cells were 
re-suspended in 5ml of HBSS. 
The bone marrow cell suspensions were counted by taking 0.1ml of the solution 
and adding to 0.9ml of ammonium chloride potassium lysing buffer (ACK, Bio Whittaker, 
Inc, Walkersville, MD).  This allowed lysis of red cells within the suspension.  After 2 
minutes 4ml of HBSS was added and the suspension was centrifuged at 1400 rpm for 10 
minutes.  The supernatant was discarded and the cells re-suspended in HBSS.  The cells 
were subsequently counted after lysis of the red cells.  The main bone marrow cell 
suspension (i.e. the remaining un-lysed suspension) was then reconstituted at a dilution of 
2.5×105 cells/ml.  200ul of this cell solution was then added to 3ml of CFU media.  After 
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vortexing, the CFU media and bone marrow cells are plated, with 1.5ml per 35mm Petri 
dish, using a 3ml syringe and 16G needle.  Overall 4 plates are placed in a 150mm tissue 
culture dish.  1-2ml of water was placed into a 35mm petri dish placed in the middle of the 
150mm tissue culture dish with the cover off.  The cover for the 150mm tissue culture dish 
is placed and the CFUs are placed in a humidified incubator at 37°C for 10-14 days.   
After 10-14 days, CFU plates were inspected for colonies.  A colony consisted of 
at least 50 cells in a dense, multi-layered pile.  Colonies were picked using a 20ul pipette, 
with a sterile plugged tip.  Granulocyte, erythrocyte, monocyte, megakaryocyte (GEMM), 
granulocyte-macrocyte progenitor (GM) and burst forming units-erythroid (BFUE) 
colonies were gently aspirated (each was 3-4ul) under microscopy and dispensed into a 
microfuge tube containing 80ul of PBS.  After the screening and picking process was 
complete, the microfuge tubes were spun down at 1600 rpm for 10 minutes and the PBS 
was carefully aspirated.  CFU samples were assessed for presence of donor MHC by PCR 
amplification.  
 
4.10 IN VITRO IMMUNE RESPONSIVENESS   
 
4.10.1 Preparation of peripheral blood mononuclear cells  
Freshly heparinised whole blood was divided into 20ml aliquots in 50ml conical 
flasks.  Each aliquot is diluted approximately 1:2 with HBSS [Gibco BRL, Grand Island, 
NY]), underlayed with 10ml of Histopaque (Sigma, St. Louis, MO) and centrifuged at 
2000 rpm for 30 minutes with the brakes off.  The buffy coat is carefully separated and the 
mononuclear cells are washed once with HBSS and centrifuged at 1600 rpm for 10 
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minutes with the brakes on.  The supernatant is discarded and the pellet is inspected for 
contaminating red cells.  Any contaminating red cells are lysed with 2ml of ACK for 2 
minutes, and then quenched with 50ml of HBSS.  Cells were then spun down again at 
1600 rpm for 10 minutes with the brakes on re-suspended in 5ml of MLR medium.  All 
PBMC suspensions were kept at 4°C until used in cellular assays. 
 
4.10.2 eFluor670 proliferation dye mixed lymphocyte reaction assay  
MLR assays are well-established in vitro assays for assessing proliferative 
lymphocyte responses across MHC class II barriers. 224  PBMC from an experimental 
animal (responders) were incubated with PBMC from another animal (stimulators) that 
had been irradiated to prevent proliferation.  The division of T cells in the responder 
PBMC was assessed by labeling them with cell proliferation dye eFluor670 (eBioscience).   
eFluor670 is a red fluorescent dye that binds to any cellular protein containing 
primary amines.  As cells divide, the dye is distributed equally between daughter cells for 
up to 6 generations.  eFluor670 is light sensitive, requiring cells to be labelled in the hood 
with the lights off.  One 500ug vial of eFluor 670 was reconstituted with 252ul of 
anhydrous DMSO for a stock concentration of 2.5mM.  Aliquots (15ul) were made and 
subsequently stored at -20°C.   
Responder cells were counted, then washed with 50ml of HBSS and centrifuged at 
1600 rpm for 10 minutes with the brakes on.  The supernatant was discarded and the pellet 
reconstituted in HBSS at a concentration of 2×107 cells/ml.  An eFluor670 stock aliquot is 
thawed.  A 5uM solution of eFluor670 was prepared by adding 10ul of 2.5mM eFluor670 
stock to 5ml of HBSS.  Under vortex agitation, equal volumes of the 5uM eFluor670 
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solution was added to responder PBMC and incubated at 37°C for 10 minutes in the dark, 
vortexing every 2-3 minutes.  After 10 minutes, the labeling process was stopped by 
adding 2ml of FBS and 4-5 volumes of CML media.  The labeled responders were left on 
ice for 5 minutes and then HBSS was added to make the solution upto 50ml.  This was 
centrifuged at 1600 rpm for 10 minutes with the brakes on.  The cells were washed with 
50ml of HBSS twice more and centrifuged at the same speed between washes.  The 
responder cells were finally counted and re-suspended in MLR media at 4×106 cells/ml.   
Stimulator PBMC from donor or donor MHC matched animals were counted and 
suspended in MLR media at 4×106 cells/ml and then irradiated under 2500cGy.  Labeled 
responder and irradiated stimulator cells were plated in quadruplicates together in 96 well 
plates (Costar Corning; Lowell, MA, USA).  Stimulator responses to self, donor and third-
party were plated and incubated for 5 days at 37˚C in 5% C02 and 100% humidity.  
Following this, cell proliferation of responder cells was analysed under flow cytometry 
using a FACSCalibur (Becton Dickinson, USA). 
 
4.10.3 [3H]-thymidine mixed lymphocyte reaction assay  
3H-thymidine MLR assays are in vitro assays that can determine proliferation 
across MHC class II barriers.  MLR responses to self, donor and third-party were 
determined in a single assay for each animal.  Responder PBMC from recipient animals 
was prepared and counted.  Responder and stimulator PBMC were diluted to a 
concentration of 4×106 cells/ml in MLR media.  Stimulator PBMC were irradiated at 
2500cGy.  100ul of stimulator PBMC was pipetted into the appropriate wells of a flat 
bottomed 96 well plate (Costar Corning; Lowell, MA, USA).  Each stimulator-responder 
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combination was plated in quadruplicates.  After a 5 day incubation, 1 microcurie (uCi) of 
3H-thymidine was added to each well, followed by an additional 5 hour incubation under 
the same conditions.  3H-thymidine incorporation was determined in quadruplicate 
samples by harvesting plates using a Cell Harvester and then counting filter mats with a 
beta-scintillation counter.  Absolute counts were compensated for background and then 
expressed as a stimulation index (SI), calculated as SI = average counts per minute (cpm) 
for a responder– stimulator pair per cpm of the same responder stimulated by an 
autologous stimulator.   
Exogenous IL-2 3H-thymidine MLRs were performed to assess for evidence of 
anergy, with addition of 5U/ml porcine IL-2 per well at the start of the MLR culture.  
Reversal of donor-specific non-responsiveness was analysed in comparison with control 
assays without IL-2. 	
	
4.10.4 Cell-mediated lymphocytotoxicity assay 
CML assays are in vitro assays to assess the killing or lysis of target cells by 
cytotoxic T cells.  PBMC from an experimental animal are incubated with irradiated 
stimulator PBMC from another animal (the responder and stimulator cells are termed an 
effector group).  After a 6 day incubation, the effector groups are harvested and then 
incubated with stimulated PBMC targets that have been labeled with 51Cr.  As the labeled 
target cells are lysed by the cytotoxic T cells in the effector groups, 51Cr is released into 
the medium.  The amount of 51Cr released is proportional to the number of targets cells 
lysed.   
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Stimulator and responder PBMC are prepared and cells are counted and suspended 
in CML media at 4 × 106 cells/ml.  Stimulator cells are irradiated at 2500cGy.  To set up 
effector groups, 1ml of responder cells and 1ml of irradiated stimulator cells are each 
pipetted into 8 wells of a 24 well plate.  Plates were incubated for 6 days at 37° in 5% 
carbon dioxide and 100% humidity.  On day 5 target cells were prepared by processing 
blood and making PBMC suspensions in CML media at 6 × 106 cells/ml.  5ml of the target 
cell suspension is pipetted into a 25cm2 flask.  10ul of phytohemagglutinin (M-form; Life 
Technologies, Gaithersburg, MD) is added to the cell suspensions in these flasks to 
stimulate cells and create lymphoblast targets.  These stimulated target cells were left 
overnight in the incubator.  Two target cells were tested in each assay: (1) PBMCs MHC 
matched to the donor and (2) third-party PBMCs. 
On day 6, targets were harvested by pipetting up and down several times and 
transferring to 15ml conical tubes.  These were centrifuged at 1400 rpm for 10 minutes at 
room temperature.  The supernatant was discarded and the pellet was re-suspended in 
0.3ml of CML takedown media.  0.3ml of 51Cr (0.3mCi) is added to each target and the 
target cells are incubated in the radioactive incubator at 37°C for 2 hours, with cells 
agitated every 2 hours by ratcheting or gentle vortexing.  While target cells are labeling 
with 51Cr in the incubator, effectors are harvested.  The effector groups are removed from 
the incubator and harvested by gently pipetting up and down several times before 
transferring to 50ml tubes.  The cells are centrifuged at 1400 rpm for 10 minutes at 4°C, 
the supernatant is discarded and the pellet re-suspended in 2ml of takedown media.  Cells 
are counted at 1/10 dilution (i.e 10ul of cells are added to 90ul of trypan blue dye).  The 
effector groups are then diluted with further takedown media to a final concentration of 5 
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× 106 cells/ml.  The effectors are subsequently placed on ice until plating with the target 
cells.   
Each effector group is incubated with target cells in triplicate at effector to target 
(E:T) ratios of 100:1, 50:1, 25:1 and 12.5:1.  Separate plates are used for each target.  
100ul of takedown media is pipetted into each of the wells designated for the 50:1, 25:1, 
12.5:1 E:T. 200ul of each effector group is pipetted into each of the 100:1 E:T wells.  
Using a multi-channel pipettor, 100ul  is removed from each of the 100:1 E:T wells and 
transferred to the 50:1 E:T wells and mixed by gently pipetting up and down.  100ul of 
cells are transferred from the 50:1 E:T wells to the 25:1 E:T wells and mixed.  This 
process is repeated from the 25:1 E:T cells to the 12.5:1 E:T wells.  Following pipetting 
and mixing in the 12.5:1 E:T wells, 100ul of cell solution is discarded.   
Prior to plating with effector groups, targets are removed from the incubator, 
washed and counted.  After removing targets from the incubator, 10ml of takedown media 
were added to each conical.  The targets were then centrifuged at 1400 rpm for 10 minutes 
at 4°C.  The supernatant was discarded and the pellet re-suspended by ratcheting.  The 
washing step was completed twice more before the cells were re-suspended in 2ml of 
takedown media.  The target cells were counted at a 1/10 dilution and re-suspended in 
takedown media at a concentration of 5 × 104 cells/ml.  100ul of target cells is added to 
each well of the appropriate effector groups.  Each plate contained triplicate MAX 
(maximum lysis of target cells) and SPONT (background lysis of target cells) wells to 
serve as controls.  MAX wells contain 100ul of 51Cr labeled target cells with 100ul of 5% 
NP40, while SPONT wells contained 100ul of 51Cr labeled target cells with 100ul of 
takedown media.   
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Plates were centrifuged at 800-1000 rpm for 5 minutes with the brakes off and 
subsequently placed in the 37°C incubator for 5.5 hours.  At the end of the incubation 
period, plates were centrifuged again at 800-1000 rpm and supernatants were harvested by 
using the Skatron collection system (Skatron, Sterling, VA), and 51Cr release was 
determined on a gamma counter (Micromedics, Huntsville, AL).  The results were 
expressed as a percentage of specific lysis and calculated as follows: Percentage of 
specific lysis = ((Experimental release [cpm] - Spontaneous release [cpm]) / (Maximum 
release [cpm] - Spontaneous release [cpm])) × 100 
 
4.10.5 CD25+ depletion assays  
 The role of CD25+ cells in maintaining non-responsiveness in vitro was examined 
by performing CD25+ cell-depleted MLR and CML assays using magnetic activated cell 
sorting (MACS).  PBMC were stained using biotinylated anti-swine α-CD25 Bio 
(231.3B2), followed by streptavidin phycoerythrin (PE) exposure and depleted using α-
PE beads and LD columns (Miltenyi Biotech, Cambridge, MA) prior to plating in MLR or 
CML assays. 
 
4.11 SKIN RESIDENT LEUKOCYTE CHARACTERISATION  
	
Punch biopsies taken from the VCA and host skin were placed overnight in 
digestion buffer (500ml RPMI with L-Glutamine, 30ml of FBS, 5.4ml of 1M HEPES 
Buffer, 5ml of DNASE I, 5ml of penicillin/streptomycin and 5ml primacin) and 10% 
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dispase.  The following day, the epidermis was separated from the dermis using a pair of 
fine forceps.  
The dermis was added to digestion buffer with collagenase and placed in an 
incubator at 37°C.  The dermis samples were filtered, centrifuged and re-suspended in 
flow cytometry media.  The cells were stained with the following swine specific 
antibodies: CD3 (898H2-6-15), CD4 (74-12-4), CD8α (76-2-11), CD16 (G7) and PAA 
(1038H-10-9).  They were subsequently analysed under flow cytometry using a 
LSRFORTESSA (Becton Dickinson).  
  Epidermis samples were placed in HBSS with trypsin.  Samples were agitated on a 
heat shaker for 30 minutes.  Digestion buffer was subsequently added to dilute the trypsin.  
Epidermis samples were then centrifuged and re-suspended in flow cytometry media.  The 
cells were stained with the same antibodies as the dermal samples and then acquired by 
flow cytometry using a LSRFORTESSA (Becton Dickinson). 
 
4.12 ASSESSMENT OF ALLOANTIBODY  
	
The presence of anti-donor immunoglobulin (IgM and IgG) in the serum of 
experimental swine was examined by indirect flow cytometry using a Becton Dickinson 
FACSCalibur to determine the SLA-binding specificity of the antibody.  Fluorescein 
isothiocyanate (FITC)-labeled goat anti-swine IgM or IgG polyclonal antibodies were 
used as secondary reagents (Kirkegaard & Perry Laboratories Inc, Gaithersburg, MD).  
For staining, 1 × 106 cells per tube of donor-type PBMCs were re-suspended in 100ul 
HBSS containing 0.1% bovine serum albumin and 0.05% NaN3 and incubated for 30 
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minutes at 4°C with 10ul decomplemented test sera (neat).  After two washes, a saturating 
concentration of FITC-labeled goat anti-swine IgM or IgG was added and incubated for 30 
minutes at 4°C.  After a final wash, cells were analysed by means of flow cytometry with 
propidium iodide (PI) gating to exclude dead cells.  Both normal pig serum and pre-
transplant sera from each experimental animal were used as controls for specific binding. 
The presence of cytotoxic antibodies to cell surface antigens in the serum of 
experimental swine was determined using an antibody-complement reaction, followed by 
a dye-exclusion assay, and flow cytometry to determine the amount of target cell lysis.  
Sera of the experimental animals were serially diluted with cytotoxicity media consisting 
of 100ml of Media 99 (Mediatech, Manassas, VA, USA) and 2ml of decomplemented 
FBS in a 96-well plate format.  1.25 × 105 target cells were added to each well and 
incubated for 15 minutes at 37°C.  Prior to acquisition, 7-Aminoactinomycin D (7-AAD), 
a fluorescent dye that intercalates into double-stranded nucleic acids and is excluded by 
viable cells, was added to each sample to detect lysed cells.  
  
99 
	
 
 
 
 
 
 
 
RESULTS 
	  
100 
	
5.  STABLE MIXED CHIMERISM AND DONOR-SPECIFIC NON-
RESPONSIVENESS IS ESTABLISHED ACROSS MHC CLASS I AND 
MHC CLASS II BARRIERS 
 
5.1 NON-MYELOABLATIVE CONDITIONING AND HSCT 
	
5.1.1 Trial of donor conditioning 
 During previous attempts to administer MGH miniature swine with IL3 and pSCF 
for mobilisation of HSCT, some animals had poorly tolerated conditioning and clinically 
deteriorated.226  Prior to commencing the experimental groups, therefore, a trial of 
cytokine treatment and HSCT mobilisation was attempted.  Animal 21902 received daily 
intramuscular injections of IL3 and pSCF.  Consistent with previous experiments, the 
animal displayed a flushed appearance on day 2 and remained clinically well for the first 4 
days of cytokine mobilisation (Figure 5.1).  
 
 
 
Figure 5.1.  Flushed skin appearance of donor animals treated with IL3 and pSCF. 
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On the fifth day of cytokine mobilisation, animal 21902 started leukapheresis for 
isolation of CM-PBSC.  After eight hours of leukapheresis, the animal became more 
lethargic, developed a deep red colour and started developing purpuric rashes.  The 
veterinarian was consulted and the leukapheresis was continued.  At the end of the fifth 
day, the animal received another dose of cytokines and was placed in its cage.  Following 
administration of the cytokines, the purpuric rashes became more widespread and the 
animal developed diarrhea.  Under advice from the veterinarian, the animal was 
rehydrated with intravenous fluids and closely monitored overnight.  Following 
commencement of leukapheresis on day 6, the clinical condition of 21902 further 
deteriorated and the decision was made, with veterinary input, to euthanise the animal.  
Following sacrifice, a necropsy was performed revealing congested lungs, with areas of 
infarction and congested kidneys (Figure 5.2).  Histological analysis of tissue biopsies 
taken from the lungs were consistent with disseminated intravascular coagulation (DIC).  
Blood cultures taken from the animal prior to sacrifice grew Arcanobacterium pyogenes.    
 Following the death of this animal, the protocol for donor conditioning and 
cytokine preparation were analysed.  Sepsis, contamination of cytokines and inaccurate 
dosing of cytokines were considered as possible causes for mortality in animal 21902.  As 
a result new batches of cytokines were used for the next set of experiments, and the 
condition of animals chosen for HSCT donors was carefully monitored before and after 
administration of cytokines for signs of infection. 
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Figure 5.2.  Lung specimen from post-mortem of animal 21902. 
Appearances of the lungs of animal 21902 demonstrated areas of infarction and 
congestion.   
 
5.1.2  Cytokine mobilisation of donor experimental animals 
	  For the experimental groups, donor and recipient animals were selected from the 
MGH miniature swine herd to allow a 2-haplotype mismatch at MHC class I (SLAgg 
donors into SLAdd recipients) or MHC class II (SLAgg donors into SLAcc recipients) 
(Figure 5.3).  
Animals 21134, 22061, 21167 and 21466 (SLAgg) underwent cytokine 
mobilisation with IL3 and pSCF, without the morbidity seen with the earlier trial of 
conditioning.  Animals demonstrated a flushed appearance without developing 
coagulopathies or gastrointestinal tract disturbance.  The target doses of 15 × 109 cells/kg 
per recipient animal were mobilized from each donor animal.  The haematological 
parameters of each animal during cytokine treatment are demonstrated in Table 5.1.  
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During administration of cytokines, a general increase in the peripheral white cell count 
(WCC) was seen.  Following the commencement of leukapheresis, there was a decline in 
the haemoglobin (Hb) and platelet levels, consistent with loss of red blood cells and 
platelets in the leukapheresis product.  The WCC in animals 22061 and 21167 rapidly 
increased on the final day of leukapheresis, in comparison with animals 21134 and 21466.  
Leukapheresis was tolerated well by all experimental donor animals, with the appetite and 
overall activity levels of all animals remaining stable.  
 
Day 21134 22061 21167 21466 
Hb WCC Neut Plt Hb WCC Neut Plt Hb WCC Neut Plt Hb WCC Neut Plt 
0 12.8 18.74 4.62 527 - - - - 11.2 14.18 5.77 559 10.2 18.58 10.33 578 
1 12.5 18.02 8.87 609 - - - - 11.1 18.76 8.72 495 10.6 16.98 7.44 436 
2 - - - - 12.4 20.74 10.42 340 - 23.28 11.78 383 11.6 18.30 12.57 454 
3 9.9 16.00 6.14 408 12.4 19.76 10.76 260 15.1 19.28 9.00 302 14.0 15.70 11.04 219 
4 - - - - 9.8 27.86 13.75 259 16.4 23.12 9,72 289 - - - - 
5 11.3 20.08 10.24 509 11.5 28.90 17.00 439 9.7 27.16 15.58 618 9.8 21.74 12.36 360 
6 7.2 19.12 9.68 492 9.9 23.14 11.75 212 6.8 20.04 10.20 228 11.6 19.54 11.55 557 
7 10.1 26.64 8.50 - 9.4 41.00 21.00 204 7.4 44.42 30.81 251 10.7 17.06 11.94 320 
Normal ranges: Hb 10 – 16 g/dl, WCC 11 - 22 k/ul, Neut 3.1 – 11.2 k/ul, Plt 325 – 715 k/ul.   
Table 5.1.  Haematological values during cytokine-mobilisation and leukapheresis of 
donor animals   
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Figure 5.3.  MHC matching of donor/recipient pairs.  
Donors and recipients were chosen to be fully mismatched at a) MHC class I antigens 
(SLAgg donors into SLAdd recipients) or b) MHC class II antigens (SLAgg donors into 
SLAcc recipients). 
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5.1.3  Recipient conditioning  
  Recipient animals (n=8) underwent a non-myeloablative conditioning regimen 
with 100cGy TBI, T cell depletion using CD3-IT and a 45-day course of CyA (Figure 
4.3).  CD3-IT was administered twice daily and corresponded with a reduction in the 
circulating lymphocyte count (Figure 5.4, Table 5.2).  Lymphocyte count reached a nadir 
on day 0 of the protocol, corresponding with administration of HSCT.  T cell depletion 
induced by the CD3-IT was partial and transient, and was followed by a recovery (Figure 
5.4). 
 
 
Day 21656 21657 22267 22268 21508 21509 22005 22006 
-4 11.94 9.17 7.76 8.40 9.83 12.8 9.30 11.06 
-3 6.45 5.03 - 6.00 7.18 7.7 5.11 7.28 
-2 5.04 4.96 10.85 4.18 4.73 6.41 4.38 6.09 
-1 - - 6.58 1.36 2.74 2.42 1.15 1.69 
0 0.94 0.51 0.94 0.67 0.84 1.1 0.70 0.68 
Table 5.2.  Lymphocyte count during treatment with CD3-immunotoxin  
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Figure 5.4. Lymphocyte depletion and recovery. 
Lymphocyte depletion and recovery in a) SLAdd recipients and b) SLAcc recipients 
(normal lymphocyte range 4.3 – 13.6 k/ul). 
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After T cell depletion and TBI, recipient animals received HSCT taken by 
apheresis of cytokine-mobilised donor animals at the target dose of 15 × 109 cells/kg.  
HSCT was given over 3 days with no complications seen in any donor and recipient 
animals.  Following HSCT, VCAs consisting of primarily vascularised skin flaps were 
transplanted from donors to recipients on day 3.  CyA levels were maintained within a 
target therapeutic range (400 - 800ng/ml tough level) for 30 days and subsequently tapered 
off by day 45 (Figure 5.5).  
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Figure 5.5.  Cyclosporine A levels during conditioning. 
Maintenance and taper of CyA levels during conditioning regimen in a) MHC class I-
mismatched chimeras and b) MHC class II-mismatched chimeras.
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5.1.4  Haematopoietic recovery following conditioning 
Following T cell depletion, TBI and HSCT, SLAdd and SLAcc recipient animals 
demonstrated stable Hb levels (Figure 5.7).  Overall WCC rose between day 0 and day 5 
of conditioning, reflecting recovery of lymphocyte counts following T cell depletion 
(Figure 5.8).  Animals in both groups did not develop neutropaenia during conditioning 
(Figure 5.9).  Platelet counts of all animals steadily declined following onset of 
conditioning, corresponding with TBI on day -2 of the protocol.  Platelet count reached a 
nadir between day 9 and 11 of the protocol (Figure 5.10). 
 SLAdd animal 22268 demonstrated declining Hb, WCC and platelet levels after 
day 5.  Platelet count declined to under 25k/ul and Hb fell to 5g/dl.  Clinically, animal 
22268 developed melena and a widespread petechial rash (Figure 5.6).  The animal failed 
to improve despite supportive therapy of blood and platelets.  Following input from the 
veterinary team, the decision was made to humanely euthanise the animal on day 13 of the 
protocol.  Underlying cause of morbidity was considered to be CyA toxicity (Figure 5.5) 
 
Figure 5.6.  Rash on Animal 22268. 
Animal 22268 developed a widespread petechial rash corresponding with decline in 
platelet and Hb levels.  The animal was euthanized on day 13 of the protocol. 
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SLAcc animal 22006 was euthanised on day 18 of the protocol following an acute 
pulmonary embolism.  Animal 21509 developed a line site infection on day 18 of the 
protocol and was treated with a 7 day course of antibiotics under veterinarian guidance.  
All other recipient animals survived the conditioning regimen and completed the 
experimental course (Table 5.1).   
 
 
Donor animal 
(SLAgg) 
Recipient animal 
(SLAcc/dd) 
MHC disparity HSCT dose Recipient 
survival 
21134 (M) 21656 (F) Full class I 15 × 109cells/kg Long-term 
21657 (F) Full class I 15 × 109cells/kg Long-term 
22061 (M) 22267 (F) Full class I 15 × 109cells/kg Long-term 
22268 (F) Full class I 15 × 109cells/kg 13 days 
21167 (M) 21508 (M) Full class II 15 × 109cells/kg Long-term 
21509 (M) Full class II 15 × 109cells/kg Long-term 
21466 (M) 22005 (M) Full class II 15 × 109cells/kg Long-term 
22006 (M) Full class II 15 × 109cells/kg 18 days 
Table 5.3.  Summary of mixed chimerism induction.   
Recipient animals underwent non-myeloablative conditioning with 100cGy TBI, transient 
T cell depletion (using a CD3-IT), HSCT and a 45-day course of cyclosporine.  Long-term 
survival refers to animal survival for greater than 150 days.  M, male; F, female.
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Figure 5.7.  Haemoglobin levels for 50 days following non-myeloablative conditioning. 
Stable Hb levels in a) SLAdd (MHC class I-mismatched chimeras) and b) SLAcc (MHC 
class II-mismatched chimeras) following TBI, T cell depletion and HSCT.    
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Figure 5.8.  White cell count for 50 days following non-myeloablative conditioning. 
Steady increase in WCC seen following T cell depletion, TBI and HSCT.  Stable WCC 
seen in a) SLAdd and b) SLAcc recipient animals following non-myeloablative 
conditioning. 
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Figure 5.9.  Neutrophil levels for 50 days following non-myeloablative conditioning. 
Steady neutrophil levels in a) SLAdd recipients and b) SLAcc recipients following T cell 
depletion, TBI and HSCT.  Neutropaenia was not seen during conditioning. 
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Figure 5.10.  Platelet count for 50 days following non-myeloablative conditioning. 
Platelet levels following TBI, T cell depletion and HSCT in a) SLAdd recipients and b) 
SLAcc recipients.  Platelet count nadir is reached 9 – 11 days following TBI.  A platelet 
count of under 25 was seen in SLAdd animal 22268. 
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5.2 STABLE MIXED CHIMERISM ACROSS MHC CLASS I AND 
MHC CLASS II BARRIERS  
	
Following non-myeloablative conditioning and HSCT, mixed chimerism was 
detectable in the peripheral blood across MHC class I barriers (Figure 5.11, Appendix 1).  
Detectable donor cells were seen in CD4+ lymphocyte, CD8+ lymphocyte, monocyte, 
granulocyte, NK cell and B cell lineages.  Durable levels of mixed chimerism persisted 
following tapering of immunosuppression, lasting for the duration of the experiment.  
Chimerism levels in SLAdd recipient animals, that received HSCT across MHC class I 
barriers, are seen in Tables 5.4 - 5.6.  High levels of chimerism are seen in T cell lineages 
(CD4+ and CD8+ lymphocytes) immediately following HSCT.  On the other hand, a low 
level of chimerism is seen in the myeloid lineages (monocytes and granulocytes) for the 
first 10 days following HSCT.  This was followed by an increase in myeloid chimerism 
levels (Tables 5.4 - 5.6, Figure 5.11).  
   Stable mixed chimerism was also established in SLAcc animals who received 
HSCT across MHC class II barriers.  Chimerism persisted following cessation of 
immunosuppression, and lasted for the duration of the experiment.  Consistent with MHC 
class I-mismatched chimeras, high levels of T cell chimerism were seen soon after HSCT.  
Detectable levels of myeloid chimerism increased in the second week of the protocol 
(Tables 5.7– 5.9, Figure 5.12).   
When comparing mixed chimeras across MHC class I and MHC class II barriers, 
particular trends were observed.  In the MHC class I-mismatched setting, higher levels of 
NK cell and CD8+ lymphocyte chimerism were generally seen.   
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Figure 5.11.  Multi-lineage stable mixed chimerism in MHC class I-mismatched 
chimeras.   
Following non-myeloablative conditioning, stable mixed chimerism was detectable across 
multiple lineages on flow cytometry of peripheral blood in animals 21656, 21657 and 
22267 conditioned across full MHC class I barriers.   
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Day CD4 
lymphocytes 
CD8 
lymphocytes 
Monocytes Granulocytes NK cells B cells 
0 0 0 0 0 0 0 
7 57 75 22 21 77 81 
10 71 76 11 31 75 76 
14 49 69 45 50 76 79 
22 61 80 65 78 63 42 
28 66 83 71 82 78 - 
35 50 83 71 82 72 - 
42 57 82 73 - 86 40 
51 42 46 86 88 - 58 
73 - - 54 62 70 39. 
86 51 77 55 76 80 24 
97 51 72 50 60 96 35 
109 47 64 49 51 55 21 
118 45 66 44 52 84 16 
147 43 64 36 44 76 7 
170 37 69 36 42 74 - 
244 32 58 26 35 80 15 
	
Table 5.4.  Levels of chimerism in multiple lineages in MHC class I-mismatched chimera 
21656. 
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Day CD4 
lymphocytes 
CD8 
lymphocytes 
Monocytes Granulocytes NK 
cells 
B cells 
0 0 0 0 0 0 0 
7 51 76 8 4 54 77 
10 59 71 5 2 74 84 
14 49 76 82 45 69 80 
22 64 78 65 83 65 41 
28 73 79 72 87 88 - 
35 57 79 67 67 61 - 
42 49 71 74 56 80 52 
51 68 50 65 71 77 35 
87 36 64 49 50 92 11 
97 30 57 47 37 84 15 
109 38 61 47 42 78 11 
118 33 53 37 34 75 14 
147 26 60 30 26 77 7 
170 24 52 22 27 57 - 
244 23 50 - 18 83 9 
282 27 66 18 19 82 30 
	
Table 5.5.  Levels of chimerism in multiple lineages in MHC class I-mismatched chimera 
21657. 
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Day CD4 
lymphocytes 
CD8 
lymphocytes 
Monocytes Granulocytes NK 
cells 
B cells 
0 0 0 0 0 0 0 
3 61 81 30 11 56 79 
10 48 72 7 2 73 65 
16 48 70 22 17 56 65 
22 67 86 48 70 70 51 
30 73 87 39 85 85 77 
43 55 80 - - 91 37 
50 55 82 24 69 93 38 
57 44 79 19 28 85 36 
72 44 70 13 23 84 24 
79 40 62 7 19 77 19 
92 31 66 - - 90 25 
108 36 70 12 16 81 29 
113 41 65 5 17 93 32 
	
Table 5.6.  Levels of chimerism in multiple lineages in MHC class I-mismatched chimera 
22267.
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Figure 5.12.  Multi-lineage stable mixed chimerism in MHC class II-mismatched 
chimeras.   
Following non-myeloablative conditioning, stable mixed chimerism was detectable across 
multiple lineages on flow cytometry of peripheral blood in animals 21508, 21509 and 
22005 conditioned across full MHC class II barriers.  
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Day CD4 
lymphocytes 
CD8 
lymphocytes 
Monocytes Granulocytes NK 
cells 
B cells 
0 0 - 0 0 0 0 
7 61 57 11 3 26 81 
11 - - 39 81 36 98 
14 91 90 - - - - 
25 37 67 25 23 22 42 
28 32 68 23 30 23 76 
33 31 63 30 35 34 94 
40 60 84 53 67 55 90 
53 51 67 54 - 81 81 
65 56 70 25 31 - 60 
68 59 78 47 67 76 95 
72 53 69 32 41 69 84 
89 48 59 43 53 76 88 
98 51 73 46 50 75 91 
118 35 61 42 50 59 75 
132 38 63 66 78 90 83 
167 36 57 94 91 90 84 
	
Table 5.7.  Levels of chimerism in multiple lineages in MHC class II-mismatched chimera 
21508. 
	
	
	
	
123 
	
Day CD4 
lymphocytes 
CD8 
lymphocytes 
Monocytes Granulocytes NK 
cells 
B cells 
0 0 0 0 0 0 0 
7 - - 11 3 26 81 
11 - - 37 35 93 95 
14 47 88 - - - - 
25 25 92 16 25 14 65 
28 38 66 34 45 31 78 
33 53 82 44 47 62 88 
40 49 81 31 88 35 87 
53 - - 53 89 73 93 
65 64 81 55 63 40 57 
68 77 55 70 90 76 91 
72 50 72 55 79 67 82 
89 20 54 64 62 74 79 
98 48 72 69 70 81 83 
118 42 58 62 61 73 72 
132 38 60 53 59 76 73 
167 46 64 - - 48 64 
202 43 48 49 53 55 62 
232 50 61 53 55 52 56 
331 44 56 43 55 67 51 
492 50 61 53 54 62 56 
	
Table 5.8.  Levels of chimerism in multiple lineages in MHC class II-mismatched chimera 
21509. 
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Day CD4 
lymphocytes 
CD8 
lymphocytes 
Monocytes Granulocytes NK 
cells 
B cells 
0 0 0 0 0 0 0 
3 73.6 85.9 7.41 18.7 44.9 99.7 
6 77.3 84.1 4.01 0.4 52.7 93.4 
15 71.9 82.3 28.6 12.2 26.2 89.8 
21 65.5 75.9 34.8 23.8 64.7 86.9 
30 68.4 72.6 35.8 43.8 33.8 79.8 
41 68.7 67.9 45.2 41.5 69.1 81.3 
51 68.3 74.7 35.9 40.2 38.7 55.2 
57 73.7 82.8 37.4 36.3 71.3 48.2 
71 62.7 81.3 47.9  54.5 39.9 
86 60.4 80.8 43.2 45.2 58 37.3 
107 52.7 73.4 56.9 63.7 58.1 57.4 
163 47.9 71.4 34.5 34.5 64.2 33.6 
179 52.4 72.2 35.7 39.9 72.6 57.7 
218 44.4 73.1 31.2 24.3 73.8 33.1 
234 56.5 70.6 29.8 29.4 77.9 27.8 
239 50.5 71.9 28.4 24.8 71.3 38 
	
Table 5.9.  Levels of chimerism in multiple lineages in MHC class II-mismatched chimera 
22005. 
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5.3 STABLE MIXED CHIMERISM IN THE THYMUS OF 
RECIPIENT ANIMALS 
	
Thymic biopsies were taken on days 50, 100 and 150 of the protocol.  Biopsy 
samples were digested and assessed for donor and recipient cell populations under flow 
cytometry.  Persisting donor cells were detectable in the thymus following non-
myeloablative conditioning and HSCT across MHC class I and MHC class II barriers 
(Figure 5.13). 
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Figure 5.13.  Thymic chimerism.  
 
Detectable donor chimerism seen following conditioning on day 150 in a) – b) MHC class 
I-mismatched chimeras and c) – d) MHC class II-mismatched chimeras.
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5.4 BONE MARROW ENGRAFTMENT FOLLOWING HSCT 
	
Following HSCT, animal 22267 (MHC class I-mismatched chimera) demonstrated 
lower level peripheral blood chimerism in the myeloid lineages (<20%) in comparison 
with other animals.  In order to assess donor haematopoeitic stem cell engraftment, a bone 
marrow biopsy was performed on day 150 of the protocol.  This was digested, plated and 
incubated for 14 days.  Subsequently, this was assessed under the microscope and CFUs 
were picked.  Following analysis of CFUs by PCR, bone marrow engraftment of donor 
haematopoietic stem cells was confirmed (Figure 5.14).     
 
	
 
Figure 5.14.  Bone marrow engraftment of donor haematopoietic stem cells. 
Bone marrow from animal 22267 was isolated at day 150 and digested, plated and 
incubated.  Colonies (GM, GEMM and BFUE) were picked and screened by PCR 
amplification of MHC class Ic to confirm engraftment of donor cells.   
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5.5 GRAFT VERSUS HOST DISEASE  
	
In animal 21508 acute cutaneous GvHD was seen on day 38 of the protocol, 
coinciding with the taper of CyA.  This was characterised by a maculopapular rash in the 
intertrigonous areas of the animal (Figure 5.15).  Histological analysis of skin biopsy 
specimens taken on this day confirmed grade 3 acute cutaneous GvHD.  The animal was 
treated with a 3-week course of steroids (1mg/kg/day prednisone for 1 week, followed by 
a 2 week taper).  Following cessation of the steroid therapy, the animal displayed 
recurrence of acute cutaneous GvHD seen on day 59 of the protocol.  Another course of 
steroids was administered (10mg/kg prednisone bolus, followed by 0.5mg/kg/day 
prednisone for one week, with a 3-week taper) with low dose CyA (target trough level 
200ng/ml).  No acute GvHD was observed following cessation of treatment.  From day 
150 of the protocol onwards, this animal demonstrated clinical features of chronic GvHD 
including diarrhea and progressive weight loss.  After consultation with the veterinarians, 
the animal was sacrificed on day 190 of the protocol.  At the time of sacrifice, the animal 
had been off all immunosuppression for over 100 days.  The VCA was unaffected by skin 
changes secondary to GvHD. 
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Figure 5.15.  Development of cutaneous GvHD. 
Animal 21508 developed a) acute cutaneous GvHD on day 38 of the protocol 
characterised by a maculopapular rash in the intertrigonous areas.  On b) histological 
analysis of skin biopsies, grade 3 GvHD was confirmed.  Following 2 courses of steroids 
b) remission of GvHD was achieved and confirmed d) histologically.  
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5.6 DONOR SPECIFIC NON-RESPONSIVENESS IN VITRO 
FOLLOWING CONDITIONING 
	
To assess the immune responses to donor antigens in MHC class I-mismatched 
chimeras, CML assays were performed at various time-points.  Prior to conditioning, 
recipient animals demonstrated responses to donor and third party (Yorkshire swine) 
antigens (Figure 5.16 - 5.17).  Following HSCT, these animals demonstrated non-
responsiveness to donor antigens that persisted following cessation of immunosuppression 
(Figure 5.16 – 5.18).  Responses to third party antigens were preserved, demonstrating 
donor-specific non-responsiveness.   
Immune responsiveness to donor antigens in MHC class II-mismatched chimeras 
was assessed with either 3H or eFluor 670 MLR assays.  Animals 21508 and 21509 
demonstrated in vitro responsiveness to donor and third party antigens pre-transplant 
(Figure 5.19 – 5.20).  Following HSCT, donor-specific non-responsiveness was 
established to donor and third party antigens, persisting long-term following cessation of 
immunosuppression (Figure 5.19 – 5.20).  MLR assays for animal 22005 did not correlate 
with the VCA clinical outcomes (Chapter 6).  Pre-assay MLR demonstrated responses to 
donor and third-party antigens (Figure 5.21).  Following HSCT, this animal demonstrated 
similar responsiveness to self, donor and third party antigens (Figure 5.21).  The failure to 
determine robust MLR responses from PBMC at this time point was attributed to animal 
22005 being under CyA treatment at this time-point.  Following cessation of 
immunosuppression, weak responses to donor and third-party were demonstrated in vitro 
(Figure 5.21). 
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Figure 5.16.  MHC class I-mismatched chimera 21656 CML in vitro responses. 
Data from MHC class I-mismatched chimera 21656 demonstrating in vitro responsiveness 
to donor antigens using CMLs.  a) The recipient showed responsiveness towards donor 
and third party antigens pre-transplant.  b) Following HSCT conditioning (week 4), donor-
specific non-responsiveness is seen, with responses to third party antigens maintained.  c) 
Donor-specific non-responsiveness is maintained long-term following cessation of 
immunosuppression. 
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Figure 5.17.  MHC class I-mismatched chimera 21657 CML in vitro responses. 
a) Responsiveness towards donor and third party antigens is seen pre-transplant.  b) 
Following conditioning and HSCT (week 4), donor-specific non-responsiveness is seen, 
with responses to third party antigens maintained.  c) Donor-specific non-responsiveness 
is maintained long-term following cessation of immunosuppression.
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Figure 5.18.  MHC class I-mismatched chimera 22267 CML in vitro responses. 
a) Pre-conditioning assay unavailable due to faulty chromium batch at time of assay.  b) 
Following conditioning and HSCT (week 2), donor-specific non-responsiveness is seen, 
with responses to third party antigens maintained.  c) Donor-specific non-responsiveness 
is maintained long-term (>100 days) following cessation of immunosuppression. 
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Figure 5.19.  MHC class II-mismatched chimera 21508 3H MLR in vitro responses. 
Data from MHC class II-mismatched chimera 21508 demonstrating in vitro 
responsiveness to donor antigens.  a) Pre-transplant the recipient showed responsiveness 
towards donor and third party antigens.  b) Following HSCT (week 4), donor-specific non-
responsiveness was seen, with responses to third party.  c) Donor-specific non-
responsiveness is maintained long-term following cessation of immunosuppression.
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Figure 5.20.  MHC class II-mismatched chimera 21509 in vitro responses. 
Data from MHC class II-mismatched chimera 21509 demonstrating in vitro 
responsiveness to donor antigens using eFluor 670 MLRs.  a) Pre-transplant the recipient 
showed responsiveness towards donor and third party antigens.  b) Following HSCT 
(week 4), donor-specific non-responsiveness was seen, with responses to third party 
antigens maintained.  c) Donor-specific non-responsiveness is maintained long-term 
following cessation of immunosuppression.
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Figure 5.21.  MHC class II-mismatched chimera 22005 in vitro responses. 
Data from MHC class II-mismatched chimera 22005 demonstrating in vitro 
responsiveness to donor antigens using eFluor 670 MLRs.  a) Pre-transplant the recipient 
showed responsiveness towards donor and third party antigens.  b) Following HSCT 
(week 4), similar responses were seen to self, donor and third party antigens.  c) Following 
cessation of immunosuppression, weak responses were seen to donor and third party in 
this animal.
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5.7 RESTORATION OF RESPONSIVENESS TO DONOR IN VITRO 
IS NOT OBSERVED WITH DEPLETION OF CD25+ CELLS  
 
In order to assess the role of regulatory T cells in maintaining donor-specific 
unresponsiveness, MLR and CML assays were performed using MACS CD25+ depleted 
PBMC from chimeric animals.  These demonstrated persistence of unresponsiveness to 
donor antigens in MHC class I-mismatched and MHC class II-mismatched chimeras 
(Figure 5.22). 
 
5.8 RESTORATION OF RESPONSIVENESS TO DONOR IN VITRO 
IS NOT OBSERVED WITH ADDITION OF IL2  
	
In order to assess a potential role for T cell anergy in maintenance of tolerance in 
chimeric animals, IL2 was added to MLR reactions.  This was done in thymidine MLR 
reactions performed early during the conditioning, immediately after cessation of 
immunosuppression and long-term following tapering of immunosuppression.  Addition 
of IL2 to MLR reactions increased overall T cell proliferation to self, donor and third 
party stimulators.  However, response to donor antigens was not restored (Figure 5.23). 
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Figure 5.22.  CD25+ cell depleted in vitro assays. 
In vitro assays using PBMC depleted of CD25+ cells demonstrated a) persistence of 
donor-specific non-responsiveness in MLR of MHC class II-mismatched chimeras.  b) 
Similarly, non-responsiveness was maintained in CD25+ depleted CMLs of MHC class I-
mismatched chimeras to self (left) and donor (middle).  Responsiveness to third party 
antigens (right) was maintained. 
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Figure 5.23.  IL-2 add-back in vitro assays. 
Addition of IL2 to MLR assays did not reverse donor-specific non-responsiveness in 
MHC class II-mismatched chimeras a) during conditioning (week 4), b) immediately after 
cessation of immunosuppression and c) long-term (>200 days).  
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6. TOLERANCE OF VCAs ACROSS MHC CLASS I/CLASS II 
BARRIERS 
 
 
6.1 MHC CLASS II-MISMATCHED CHIMERAS ARE TOLERANT 
OF VCAs BUT MHC CLASS I-MISMATCHED CHIMERAS REJECT 
VCA SKIN 
	
MHC class II-mismatched chimeric animals demonstrated rejection-free survival 
of all components of VCAs, including the skin, for the duration of study (190 to >530 
days, Figure 6.1 - 6.3, 6.8, Table 6.1).  No clinical or histological signs of rejection were 
seen during the conditioning regimen, following the tapering of immunosuppression or 
long-term (Figure 6.1 – 6.3).  Despite treatment for GvHD with steroids, animal 21508 
demonstrated long-term (>100 days), rejection-free survival of the VCA at the time of 
sacrifice (Figure 6.1, 6.8, Table 6.1).  
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Figure 6.1.  VCA time course of MHC class II-mismatched chimera 21508. 
Time-course of VCA from animal 21508 demonstrating no clinical or histological signs of 
rejection a) during the conditioning regimen, b) following the taper of immunosuppression 
or c) long-term
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Figure 6.2.  VCA time course of MHC class II-mismatched chimera 21509. 
Time-course of VCA from animal 21509 demonstrating no clinical or histological signs of 
rejection a) during the conditioning regimen, b) following the taper of immunosuppression 
or c) long-term. 
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Figure 6.3.  VCA time course of MHC class II-mismatched chimera 22005. 
Time-course of VCA from animal 22005 demonstrating no clinical or histological signs of 
rejection a) during the conditioning regimen, b) following the taper of immunosuppression 
or c) long-term.
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By contrast, all MHC class I-mismatched chimeric animals demonstrated rejection 
episodes of their VCAs.  After immunosuppression was tapered, animal 21656 
experienced 3 acute rejection episodes characterised by redness and crusting of the VCA 
(Figure 6.4).  The first 2 of these crises spontaneously resolved without treatment.  
Histological analysis of skin biopsies taken during these acute rejection episodes revealed 
grade 3-4 rejection of the VCA epidermis, with cellular infiltrate seen at the dermo-
epidermal junction (Figure 6.4).  The final acute rejection episode in animal 21656 
resulted in sloughing of the VCA epidermis on day 99, followed by re-epithelialisation 
from the surrounding host skin (Figure 6.4, 6.5, Table 6.1).  Tolerance of underlying VCA 
dermis and fascia was seen.  
 
 
Figure 6.4.  VCA time course of MHC class I-mismatched chimera (21656). 
MHC class I-mismatched chimera 21656 experienced acute rejection episodes of the VCA 
skin corresponding with a) the taper of immunosuppression, characterised by b) skin 
redness and crusting.  Sloughing of the VCA skin epidermis was seen c) following the 
final acute rejection episode on day 99.  
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Figure 6.5.  Re-epithelialisation of MHC class I-mismatched chimera VCA (21656). 
Following a) sloughing of VCA skin epidermis, b) healthy underlying dermis and fascia 
was seen.  c)-f) There was subsequent re-epithelialisation concentrically from surrounding 
healthy recipient skin.  
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Animal 21657 experienced 1 acute rejection crisis of the VCA on day 42, 
coinciding with the taper of immunosuppression.  Biopsy at this time demonstrated grade 
3-4 rejection of the VCA epidermis, and this crisis spontaneously resolved without further 
acute rejection episodes.  However, the VCA skin subsequently appeared discolored and 
thickened and serial biopsies after this rejection episode demonstrated grade 3 rejection of 
the VCA epidermis without extension to the dermis or fascia (Figure 6.6, Table 6.1).  
 
 
Figure 6.6.  VCA time course of MHC class I-mismatched chimera (21657). 
VCA time-course from MHC class I-mismatched chimera 21657 demonstrating a) an 
acute rejection episode on day 42 and b)-c) subsequent persistent thickening, 
discolouration and histological evidence of VCA epidermal rejection.  
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Animal 22267 experienced 4 acute rejection crises of the VCA corresponding with 
the taper of immunosuppression (Figure 6.7).  Initial episodes spontaneously resolved 
without immunosuppression, with histology demonstrating epidermal rejection.  During 
later rejection episodes, epidermal rejection was seen on histology, with lymphocytic 
infiltrate seen in the dermis and fascia.  The final crisis resulted in loss of the VCA 
epidermis on day 95 and the underlying VCA dermis and fascia were subsequently 
rejected on day 110 (Figure 6.7, Table 6.1). 
 
 
Figure 6.7.  VCA time course of MHC class I-mismatched chimera (22267). 
VCA time-course from MHC class I-mismatched chimera 22267 demonstrating a) –b) 
recurrent acute rejection crises following tapering of immunosuppression.  The c) final 
acute rejection crisis was followed by loss of VCA epidermis.  
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Figure 6.8.  VCA outcomes in MHC class I/MHC class II-mismatched chimeras. 
Overview of clinical and histological outcomes of VCAs in a) MHC class II-mismatched 
chimeras and b) MHC class I-mismatched chimeras. 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1.  Summary of VCA outcomes in stable mixed chimeras across MHC barriers.  
VCA MHC 
disparity Animal # 
VCA survival (days) 
Epidermis Dermis/Fascia 
Class II 
21508 Accepted (190d) Accepted 
(190d) 
21509 Accepted (>530d) Accepted 
(>530d) 
22005 Accepted (>320d) Accepted 
(>320d) 
Class I 
21656 Rejected (99d) Accepted 
21657 Accepted with histological 
features of rejection 
Accepted 
22267 Rejected (95d) Rejected (110d) 
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6.2 NO SYSTEMIC EVIDENCE OF REJECTION SEEN IN MHC 
CLASS I-MISMATCHED CHIMERAS, DESPITE LOSS OF VCA 
SKIN 
	
Despite rejection of VCA skin in MHC class I-mismatched chimeras, stable mixed 
chimerism was maintained (Figure 6.9).  In addition, donor-specific non–responsiveness 
persisted in CML reactions using PBMC and the development of circulating donor-
specific antibody was not detected (Figure 6.9).    
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Figure 6.9.  Lack of systemic rejection in MHC class I-mismatched chimeras. 
No systemic evidence of rejection is seen in MHC class I-mismatched chimeras following 
rejection of VCA skin, with a) persistence of stable mixed chimerism, b) donor-specific 
non-responsiveness demonstrated in vitro and c) - d) no evidence of alloantibody 
production.    
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6.3 RECIPIENT-TYPE LEUKOCYTES RAPIDLY INFILTRATE VCA 
SKIN FOLLOWING TRANSPLANTATION 
 
To characterise the local cell populations that may contribute to VCA 
tolerance/rejection, serial VCA and host skin biopsies were separated into epidermal and 
dermal components, and isolated leukocytes were analysed by flow cytometry.  Analysis 
of biopsies taken immediately post-VCA transplant demonstrated the presence of donor-
type cells within the VCA skin.  Subsequently, turnover of VCA skin-resident leukocytes 
is seen in all chimeric animals, with the presence of skin-resident, recipient-type 
Langerhans cells (Figure 6.10), CD4+ and CD8+ lymphocytes (Figure 6.11) detectable in 
the VCA skin as early as week 2 post-transplant.  
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Figure 6.10.  VCA Langerhans cell population analysis. 
Analysis of digested VCA biopsies under flow-cytometry allowed monitoring of cell 
populations in the epidermis.  a)-b) By gating on live cells, and staining for MHC class II 
and langerin, the presence of recipient-type Langerhans cells is seen by week 2.   
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Figure 6.11.  VCA T cell population analysis. 
Analysis of digested VCA biopsies under flow-cytometry allowed monitoring of cell 
populations in the dermis.  a) After gating on live cells and CD3+ cells, few recipient-type 
CD4+ and CD8+ lymphocytes were seen immediately post-transplant.  b) By contrast, 
recipient-type CD4+ and CD8+ lymphocytes were seen in the VCA skin by week 2.  
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6.4 CHARACTERISATION OF VCA SKIN-RESIDENT 
LEUKOCYTES 
	
Turnover of VCA skin-resident leukocytes, from donor to recipient type, was seen 
in chimeric animals.  In MHC class II-mismatched chimeras local chimerism of VCA 
skin-resident CD4+ and CD8+ lymphocytes achieved parity to that of host skin and 
peripheral blood chimerism by day 50.  Slower turnover of VCA epidermal Langerhans 
cells was seen, with local chimerism levels trending towards peripheral blood monocyte 
chimerism (Figure 6.12).  Turnover of skin-resident leukocytes is also seen in host skin of 
MHC class II-mismatched chimeras, with donor-type cells detectable in increasing 
amounts following HSCT.  After day 150, leukocyte composition of VCA skin, detectable 
under flow cytometry, was indistinguishable from host skin (Figure 6.13 – 6.15).  In MHC 
class I-mismatched chimeras, turnover of VCA skin-resident CD4+ lymphocytes is seen, 
reflecting peripheral blood and host skin chimerism in the same lineage by day 50.  
Ongoing turnover of VCA epidermal Langerhans cells are seen until before skin rejection.  
Significant turnover of VCA skin-resident CD8+ lymphocytes was seen prior to rejection, 
in comparison with host skin, with an increased proportion of CD8+ lymphocytes 
detectable in the skin (Figure 6.12).    
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Figure 6.12.  Comparison of recipient versus donor skin-resident leukocytes. 
Skin-resident leukocytes in VCA and host skin epidermis and dermis were characterised 
using flow cytometry of enzymatically digested biopsy specimens.  Representative data in 
a) 22005 (MHC class II-mismatched chimera) demonstrated turn-over of epidermal 
Langerhans cells in VCA and host skin, equilibrating after day 150 to levels reflective of 
peripheral blood monocyte chimerism.  In b) 22267 (MHC class I-mismatched chimera) 
turnover of VCA and host skin Langerhans cells were seen until loss of VCA epidermis. 
Infiltrate of recipient-type CD4+ and CD8+ lymphocytes was seen by week 2 in the VCA 
dermis of c) 22005 and d) 22267.  CD4+ lymphocyte chimerism was comparable in VCA 
and host skin dermis in MHC class II and class I mismatched chimeric animals after day 
50.  An increased proportion of recipient-type CD8+lymphocytes was seen in the VCA 
dermis of 22267 before skin rejection. 
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Figure 6.13.  Characterisation of skin resident leukocytes in VCA and host skin epidermis 
in MHC class II-mismatched chimeras. 
 
Turnover of skin resident Langerhans cells was seen in a) VCA skin and b) host skin 
following HSCT.  Recipient-type Langerhans cells infiltrate the VCA skin, while donor-
type Langerhans cells infiltrate host skin.  By day 150, the composition of VCA and host 
skin was comparable. 
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Figure 6.14.  Characterisation of skin-resident leukocytes in VCA and host skin dermis in 
MHC class II-mismatched chimeras at day 0. 
 
Characterisation of skin resident a) VCA and b) host skin dermis immediately following 
perfusion after transplantation.  VCA skin-resident CD4+ and CD8+ lymphocytes were 
predominantly donor-type, while host skin-resident CD4+ and CD8+ lymphocytes were 
predominantly recipient-type.  
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Figure 6.15.  Characterisation of skin-resident leukocytes in VCA and host skin dermis in 
MHC class II-mismatched chimeras at day 50. 
 
Characterisation of skin resident a) VCA and b) host skin dermis post-day 50.  Turn-over 
of skin resident leukocytes observed. The composition of VCA and host skin-resident 
CD4+ and CD8+ lymphocytes was now indistinguishable.
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6.5 RECIPIENT-TYPE CD8+ LYMPHOCYTES INFILTRATE THE 
REJECTING VCA SKIN OF MHC CLASS I-MISMATCHED 
CHIMERAS 
 
VCA skin biopsies taken from MHC class I-mismatched chimeras during rejection 
and analysed under immunohistochemistry showed high numbers of CD3+ cells (Figure 
6.16).  This was further characterised by flow cytometry of digested skin and revealed 
recipient-type CD8+ lymphocytes as the predominant cellular infiltrate in the rejecting 
skin (Figure 6.16), in comparison with non-rejecting host skin.  
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Figure 6.16.  Characterisation of the cellular infiltrate of rejecting VCA skin.  
 
A) Infiltrating CD3+ lymphocytes were seen in the dermis and dermo-epidermal junction 
of MHC class I-mismatched chimeras during VCA skin rejection.  B) In contrast fewer 
skin-resident lymphocytes were seen in the skin of tolerant VCAs of MHC class II-
mismatched chimeras.  C) Higher levels of CD8+ lymphocytes were seen in the rejecting 
VCA epidermis of MHC class I-mismatched chimeras compared to D) non-rejecting host 
skin.  E) Higher levels of CD8+ lymphocytes were also seen in the VCA dermis during 
rejection compared with F) non-rejecting host dermis.  The CD8+ lymphocytes in 
rejecting VCAs were predominantly recipient-type.	  
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6.6 FoxP3+ CELLS ARE SEEN IN THE SKIN OF TOLERANT AND 
REJECTING VCAs 
	
In order to characterise regulatory cells in VCAs, the presence of CD4+, CD25+ 
FoxP3+ cells was determined using immunohistochemistry and flow cytometry.  This 
revealed the presence of donor and recipient FoxP3+ cells in the VCAs of all chimeric 
animals (Figure 6.17 – 6.19).  
 
Figure 6.17.  Characterisation of VCA FoxP3+ cell population. 
Using immunohistochemistry, FoxP3+ cells can be seen in the VCA skin of a) MHC 
class-II mismatched chimeras and b) MHC class I-mismatched chimeras, with a high 
number of FoxP3+ cells visualised during rejection episodes.  Flow cytometric analysis of 
VCA local FoxP3+ cells demonstrated the presence of donor and recipient-type cells in 
the VCAs of c) MHC class II and d) MHC class I-mismatched chimeras.  
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Figure 6.18.  Characterisation of VCA skin-resident FoxP3 cells in MHC class II-
mismatched chimeras post-day 50. 
CD4+ CD25+ FoxP3+ cells in a) VCA skin and b) host skin were a combination of 
recipient and donor-type. 
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Figure 6.19.  Characterisation of VCA skin-resident FoxP3 cells in MHC class I-
mismatched chimeras post-day 50. 
CD4+ CD25+ FoxP3+ cells in a) VCA skin and b) host skin were a combination of 
recipient and donor-type.
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6.7 SURVIVAL OF DONOR SPLIT-THICKNESS SKIN GRAFTS 
PLACED FOLLOWING VCAs 
 
In order to assess the robustness of tolerance, split-thickness skin grafts taken from 
donor animals were placed on chimeras greater than 150 days after the VCA transplant.  
MHC class II-mismatched chimeras demonstrated survival of donor skin grafts for the 
duration of the experiment.  On the other hand, they were rapidly lost (14 to 18 days) from 
MHC class I-mismatched chimeras (Figure 6.20).  
 
 
Figure 6.20.  Tolerance versus rejection of donor split-thickness skin grafts. 
MHC class II-mismatched chimeras demonstrate a) tolerance of donor split-thickness skin 
grafts placed after VCAs and HSCT.  By contrast b) MHC class I-mismatched chimeras 
reject donor skin grafts after rejection of VCA skin.  
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6.8 INDUCTION OF TOLERANCE ACROSS MHC CLASS II 
BARRIERS MAY INDUCE LINKED SUPPRESSION 
 
To determine whether tolerance across MHC barriers could extend to non-exposed 
minor antigens, all chimeric animals received donor MHC-matched, miHA-mismatched 
skin grafts.  MHC class II-mismatched chimeras experienced prolonged acceptance of 
donor MHC-matched, miHA-mismatched skin grafts with survival varying between 57 to 
362 days (Table 6.2).  By contrast, survival of donor MHC-matched, miHA-mismatched 
skin grafts varied from 14 to 40 days in MHC class I-mismatched chimeras (Table 6.2). 
To assess whether prolonged acceptance of miHA in MHC class II-mismatched 
chimeras was linked to establishing tolerance across full MHC class II barriers, these 
animals subsequently received a recipient MHC-matched, miHA-mismatched skin graft 
(Figure 6.21) and an alternative donor MHC-matched, miHA-mismatched skin graft.  In 
animal 21509, the recipient MHC-matched, miHA-mismatched skin was lost on day 43, 
but the second donor MHC-matched, miHA-mismatched skin graft was lost on day 144.  
Animal 22005 lost both donor MHC-matched and recipient MHC-matched skin grafts by 
day 14.  
Despite rejection of donor MHC-matched, miHA-mismatched skin grafts and 
recipient MHC-matched, miHA-mismatched skin grafts, tolerance of VCAs and donor 
skin grafts persisted in MHC class II-mismatched chimeras.  This confirmed persistence of 
tolerance to donor MHC antigens.  
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Figure 6.21.  Survival of miHA-mismatched split-thickness skin grafts. 
Skin graft survival: a) Donor MHC-matched, miHA-mismatched skin grafts persisted 
long-term (>300 days) in animal 21509 (stable MHC class II-mismatched chimera).  b) 
Recipient MHC-matched, miHA-mismatched skin graft by comparison rejected by day 43 
with clinical findings confirmed on histology. 
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Animal 
number 
MHC 
disparity 
Chimerism Donor MHC 
matched skin 
graft survival 
21509 
Full Class II 
 
Stable multilineage 
 
362 
22005 57 
21656 
 
Full Class I 
 
Stable multilineage 
14 
21657 40 
22267 18 
 
Table 6.2.  Summary of donor MHC-matched, miHA-mismatched skin graft survival. 
 
 
6.9 LOSS OF SKIN GRAFTS WAS MEDIATED BY MHC CLASS I 
ASSOCIATED ANTIGENS  
 
Following rejection of donor MHC-matched, miHA-mismatched skin grafts, MHC 
class II-mismatched chimeric animals develop CML responses to donor-matched PBMC 
demonstrating sensitisation to MHC class I-associated minor antigens (Figure 6.22).  
On the other hand, MHC class I-mismatched chimeras remain non-responsive to 
donor-matched antigens on CML despite rejection of VCA skin, donor skin grafts and 
donor MHC-matched, miHA-mismatched skin grafts (Figure 6.22). 
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Figure 6.22.  Restoration of CML responses after skin graft rejection. 
CML responses are developed following rejection of donor MHC-matched, miHA-
mismatched skin grafts in a) MHC class II-mismatched chimeras but not b) MHC class I-
mismatched chimeras.  
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7. VCA TOLERANCE ACROSS MHC BARRIERS USING 
IMMUNOMODULATORY STRATEGIES 
 
7.1 KIDNEY INDUCED TOLERANCE 
 
Using the kidney induced tolerance model, we explored whether tolerance of 
allogeneic MHC class II could facilitate acceptance of skin via immunomodulatory 
pathways alone.  
Transplant donors and recipients were selected from the MGH miniature swine 
herd (Figure 4.2).  In group 1, to generate an MHC disparity across a haploidentical 
barrier (1-haplotype class I and class II), SLAac animals received heart and kidney 
transplants from SLAad donors with 12 days of tacrolimus, followed after 100 days with a 
donor-matched SLAad myocutaneous VCA transplant without further immunosuppression 
(Table 7.1).  In group 2, to generate a MHC disparity across a full MHC mismatch barrier 
(2-haplotypes class I and class II), SLAcc animals received heart and kidney transplants 
from an SLAdd donor with 12 days of tacrolimus, followed after 100 days with a donor-
matched SLAdd myocutaneous VCA transplant without further immunosuppression (Table 
7.1).  Outcomes were compared with the historical control groups (3 and 4), in which 
SLAdd recipient animals received kidney transplants from SLAgg donors with a short 
course of high-dose immunosuppression to induce tolerance across a full MHC class I 
disparity (2-haplotypes class I).  Delayed VCA transplants were performed from donor-
matched animals.  All recipients demonstrated significant in vitro anti-donor activity by 
CML and/or MLR before organ transplantation (Figure 7.1). 
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Figure 7.1.  Pre-transplant anti-donor response of heart-kidney-VCA recipient. 
Animal 21270 demonstrated a) CML responses to donor and third party antigens and b) 
MLR responses to donor and third party antigens. 
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7.2 EARLY SKIN AND MUSCLE LOSS IN RECIPIENTS OF 
HAPLOIDENTICAL MHC-MISMATCHED VCAs 
 
To determine whether tolerance achieved across a haploidentical MHC class I and 
class II mismatch could confer tolerance of a VCA, 2 animals (SLAac) who had 
demonstrated long-term tolerance of heart and kidney allografts (heart and kidney 
allografts from the same SLAad donor) for >100 days underwent VCA transplantation 
(VCA allograft from a different SLAad donor) (group 1, Table 7.1).  The VCA on group 1 
animal 21270 showed clinical and histological signs of epidermis rejection by POD 13; 
VCA dermis and muscle were rejected by POD 29.  The VCA on group 1 animal 21517 
showed clinical and histological signs of epidermis rejection by POD 13 (Figure 7.2, 7.3); 
VCA dermis and muscle were rejected by POD 31 (Figure 7.2).  In contrast, 5 of 6 
animals tolerant of kidneys across a MHC class I mismatch who then received a MHC 
class I-mismatched VCA demonstrated VCA epidermis rejection within 85 days but 
showed long-term acceptance of VCA dermis and muscle (groups 3 and 4, Table 7.1). 
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Figure 7.2.  Gross appearance of VCAs. 
Representative clinical images of VCAs from a) group 1 animal 21517 and b) group 2 
animal 22025 by post-operative day.  Animals in both groups showed patchy areas of 
necrosis starting on post-operative day 7 which progressed to epidermal sloughing.  
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Figure 7.3.  Histology from representative VCA biopsies. 
a) Biopsies from group 1 animal 21517 shows grade 4 rejection of the epidermis and acute 
rejection of the muscle with endarteritis.  b) The VCA biopsy from group 2 animal 22025 
shows grade 4 rejection of the epidermis and acute rejection of the muscle with 
endarteritis.  
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7.3 EARLY SKIN AND MUSCLE LOSS IN RECIPIENTS OF FULL 
MHC-MISMATCHED VCAs 
	
To determine whether tolerance achieved across a full MHC mismatch barrier (2-
haplotype MHC class I and class II mismatch) through immunomodulatory strategies 
could confer tolerance to a VCA, 2 animals (SLAcc) who had been long-term tolerant of 
heart and kidney allografts (heart and kidney allografts from the same SLAdd donor) for 
>100 days underwent VCA transplantation (VCA allograft from a different SLAdd donor) 
(group 2, Table 7.1).  The VCA on group 2 animal 21740 showed clinical and histological 
signs of epidermis rejection by POD 14; VCA dermis and muscle were rejected by POD 
35.  The VCA on group 2 animal 22025 showed clinical and histological signs of 
epidermis, dermis, and muscle rejection by POD 30 (Figure 7.2, 7.3). 
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Table 7.1.  Survival of VCAs transplanted across MHC barriers with immunomodulatory 
strategies alone. 
1Animals previously published in Cetrulo et al, Transplantation 2013.198  Group 3 animals 
received a MHC class I-mismatched VCA transplant less than 70 days after primary 
kidney transplant  
2Animals previously published in Cetrulo et al, Transplantation 2013.198  Group 4 animals 
received a MHC class I-mismatched VCA transplant at least 100 days after kidney re-
transplantation, without further immunosuppression (i.e. >200 days after primary 
transplantation). 
 
 
	  
Group  MHC disparity Animal # 
MHC of Allografts VCA survival (days) 
Donor Recipient Epidermis Dermis/Muscle Heart Kidney VCA 
1 Haploidentical 21270 AD AD AD AC 15 29 21517 AD AD AD AC 13 31 
2 
Full mismatch (full 
MHC class I and 
MHC class II) 
21740 DD DD DD CC 14 35 
22025 DD DD DD CC 30 30 
31 Full MHC class I 
19842 - GG GG DD 40 accepted 
19941 - GG GG DD 28 accepted 
20652 - GG GG DD 30 accepted 
42 Full MHC class I 
18954 - GG, GG GG DD >200 accepted 
18958 - GG, GG GG DD 85 accepted 
18955 - GG, GG GG DD 45 accepted 
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7.4 DONOR MHC-SPECIFIC IN VITRO RESPONSIVENESS IS 
REGAINED AFTER VCA TRANSPLANT 
 
To assess immune competence in recipients before and after VCA transplant, MLR 
and CML assays were performed.  Group 1 animal 21517, which had been donor-specific 
unresponsive by CML and MLR prior to VCA transplant, regained weak donor-
responsiveness after VCA transplant (Figures 7.4 and 7.5).  Group 1 animal 21270 already 
showed positive donor-specific response by CML and MLR at the time of VCA 
transplant.  Both group 2 animals showed donor-specific unresponsiveness by CML and 
MLR prior to VCA transplant.  After VCA transplant, group 2 animal 22025 regained 
donor-responsiveness by CML and MLR (Figures 7.4 and 7.5); Group 2 animal 21740 
also regained donor-responsiveness by MLR, but remained unresponsive to donor by 
CML.  Animals in historical groups 3 and 4 displayed donor-specific hyporesponsiveness 
or unresponsiveness by CML before and after VCA epidermis rejection.   
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Figure 7.4.  CML assays from heart-kidney-VCA recipients. 
Percent-specific lysis is plotted as a function of effector:target ratio.  Response against 
donor-type (SLAad or SLAdd) targets before VCA transplant and 30 to 31 days after VCA 
transplant for a) group 1 animal 21517 and b) group 2 animal 22025.  Donor-specific non-
responsiveness is seen prior to VCA transplantation.  Following VCA rejection responses 
to donor antigens are re-established.  
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Figure 7.5.  MLR assays from heart-kidney-VCA recipients. 
Stimulation indices to self, donor-type (SLAad or SLAdd), and third-party (Yorkshire) 
peripheral blood mononuclear cells before VCA transplant and 30 to 31 days after VCA 
transplant.		Donor-specific non-responsiveness is seen prior to VCA transplantation.  
Following VCA rejection MLR responses to donor antigens are re-established.  
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7.5 LACK OF CIRCULATING ALLOANTIBODY FOLLOWING VCA 
REJECTION 
 
To determine whether rejection of VCA led to alloantibody formation, flow 
cytometry analysis of anti-donor antibodies was performed.  Animals in group 1 and 
group 2 did not develop any detectable circulating levels of anti-donor IgM or IgG 
antibody before or after VCA transplant, despite VCA rejection (Figure 7.6).   
 
Figure 7.6.  Alloantibody response of heart-kidney-VCA recipients.  
Levels of circulating a) IgM and b) IgG alloantibody were measured by flow cytometry in 
groups 1 and 2.  Data were normalised to the mean fluorescence intensity of negative 
control values to plot normalised mean fluorescence intensity as a function of POD.  HK 
tx, heart-kidney transplant; s/p, status post. 
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7.6 HEART AND KIDNEY ALLOGRAFT TOLERANCE IS 
MAINTAINED DESPITE VCA REJECTION 
 
Animals were monitored by serial biopsies to determine whether VCA rejection 
affected tolerance of heart or kidney allografts.  Heart and kidney allografts were biopsied 
up to 40 days after VCA transplant in group 1 and up to 65 days after VCA transplant in 
group 2.  Animals in both groups showed no clinical or histological signs of heart 
rejection (Table 7.2).  Animals in group 1 showed no signs of kidney rejection, though 
animal 21270 developed pyelonephritis with a corresponding increase in creatinine (Table 
7.2).  Group 2 animal 22025 showed no signs of kidney rejection; however, group 2 
animal 21740 had chronic rejection changes present prior to VCA transplantation.  
Nodular lymphocytic infiltrates associated with the vasculature of the kidney defined as 
“Treg-rich organized lymphoid structures” were found in all animals on kidney biopsies 
before VCA transplantation and after VCA rejection (Figure 7.7). 
 
Table 7.2.  Heart and kidney graft outcomes after VCA transplant. 
 
* chronic rejection of renal allograft seen before and after the VCA. 
 
 
Group VCA MHC disparity 
Animal 
# 
Heart Histology/Function Kidney Histology/Creatinine (ummol/L) 
Before VCA After VCA Before VCA After VCA 
1 Haploidentical 21270 0/sinus 0/sinus 0/150 1/2051 21517 0/sinus 0/sinus 1/150 1/159 
2 Full MHC mismatch  
21740 0/sinus 1/sinus */371 */743 
22025 0/sinus 0/sinus 0/114 0/62 
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Figure 7.7.  Histology from representative kidney samples taken prior to VCA 
transplantation and after VCA rejection. 
Group 1 animal 21517 and group 2 animal 22025 demonstrate the presence of organised 
lymphoid structures before and after VCA rejection.  
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8.1 NON-MYELOABLATIVE CONDITIONING FOR INDUCTION OF 
MIXED CHIMERISM 
	
	 In this study I established stable mixed chimerism in miniature swine across full 
MHC class I or MHC class II barriers.  Generating stable mixed chimeras in large animal 
models using non-myeloablative conditioning has traditionally been challenging.  
Previous miniature swine, as well as rodent, studies have identified effective T cell 
depletion as an important component for successful HSCT engraftment. 124,225  Here, we 
achieved successful T cell depletion in recipient animals using CD3-IT, without observing 
any side-effects.  The dose and duration of administration of this T cell depletional agent 
was based on previous miniature swine studies of mixed chimerism. 124   
Following effective T cell depletion and TBI, recipient animals received HSCT 
from donor animals.  CM-PBSC was used as the source of haematopoeitic cells, providing 
certain advantages over BMT.  Specifically, much larger doses of stem cells could be 
mobilised, over multiple days, and donor animals could be kept alive for VCA transplants.  
The use of such large doses of HSCT facilitates establishment of chimerism using non-
myeloablative protocols. 109 
In this study, donor animals underwent cytokine mobilisation with IL3 and pSCF 
from day -5 to day 2 of the protocol, with CM-PBSC collected using leukapheresis on day 
0 to day 2.  A donor animal was conditioned with cytokines as a trial prior to commencing 
the experimental animals in this study.  This animal developed loss of appetite, diarrhea 
and DIC during leukapheresis.  Similar donor morbidity has been observed previously and 
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attributed to route of cytokine administration during conditioning.  Using a similar 
conditioning protocol in miniature swine, Matar et al. have observed poor outcomes in 
donor animals conditioned with cytokines administered subcutaneously, while animals 
receiving cytokines intramuscularly remained clinically well. 226  The recipients of donors 
that had experienced adverse reactions during leukapheresis developed haematologic and 
coagulation abnormalities, requiring blood support and failed to engraft.  The precise 
mechanisms determining the difference between donors experiencing adverse reactions 
and those that remained clinically well were not determined.  In the present study, 
cytokines were all administered intramuscularly and the cause of donor morbidity during 
the trial conditioning was not conclusively determined.  Sepsis, poor donor condition and 
contaminated cytokines were considered possible causes.  All subsequent donor animals 
conditioned for experimental purposes in this study remained clinically well.  In these 
animals, target doses of cytokines were mobilized and HSCT was well-tolerated by 
recipient animals.  
 The non-myeloablative nature of the conditioning protocol was demonstrated by 
the stable Hb, WCC and neutrophil levels following TBI, T cell depletion and HSCT in all 
animals, except 22268.  As expected platelet counts reached a nadir approximately 10 
days following TBI.  The conditioning regimen was well tolerated by recipient animals 
and few infections were seen (only animal 21509 developed a line site infection requiring 
treatment with antibiotics).  No animals, apart from 22268, required support with blood 
products such as red blood cells or platelets.  The conditioning regimen used for animal 
22268 was the same as for all other animals.  In addition, this animal received the same 
HSCT product as animal 22267 (Table 5.3).  The anaemia and thrombocytopaenia seen in 
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animal 22268 are likely to be related to CyA toxicity, as drug levels were difficult to 
control in this recipient.   
The use of a non-myeloablative conditioning protocol for induction of stable 
mixed chimerism in this study has potentially important clinical significance.  While 
conditioning regimens resulting in pancytopaenia are acceptable in the context of bone 
marrow malignancies, they are less satisfactory in non life-threatening conditions.  Given 
VCAs are fundamentally life-enhancing transplants, morbidity or mortality secondary to 
immunosuppressive medication or tolerance induction protocols are difficult to justify.  
The non-myeloablative conditioning protocol used in this study, therefore, provides a 
clinically relevant model for induction of VCA tolerance using the mixed chimerism 
approach.  
 
8.2 ESTABLISHMENT OF MIXED CHIMERISM ACROSS MHC 
BARRIERS 
	
   Following HSCT, mixed chimerism was detectable in the peripheral blood in 
multiple haematopoietic lineages across full MHC class I or MHC class II barriers.  Low 
levels of chimerism were detectable in the myeloid lineages in the initial days after HSCT.  
Increases in the levels of myeloid chimerism were seen in the second week after HSCT.  
This is consistent with donor haematopoietic stem cells engrafting within a bone marrow 
niche and then providing a source for peripherally detectable donor-type myeloid cells.  
Indicative of HSCT engraftment, all chimeric animals, except animal 22267, demonstrated 
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stable levels of myeloid chimerism following the taper of CyA. 127  Thymic chimerism, 
which has been demonstrated to be a robust predictor of allograft tolerance, was detectable 
across both MHC class I-mismatched chimeras and MHC class II-mismatched chimeras 
following cessation of immunosuppression. 127  In comparison with the other chimeras, 
animal 22267 displayed low levels of detectable macrochimerism in the peripheral blood 
myeloid lineages after cessation of immunosuppression.  To confirm engraftment of 
HSCT, bone marrow samples were processed and plated for 14 days.  Subsequently CFUs 
were picked and analysed with PCR using class Ic primers.  This confirmed bone marrow 
engraftment of donor HSCT in animal 22267.   
High levels of lymphoid chimerism were detectable in all animals immediately 
following HSCT, persisting after immunosuppression was tapered.  In addition, the 
circulating lymphocyte count was demonstrated to recover quickly following T cell 
depletion.  Consistent with previous miniature swine studies, the early, high level of 
lymphoid chimerism reflects the donor-type T cells transferred in the leukapheresis 
product and the thymic output following T cell depletion and HSCT. 124   
 
8.3 GRAFT VERSUS HOST DISEASE 
	
 HSCTs, containing T cells, performed across MHC barriers are associated with 
risk of GvHD.  Previous miniature swine experiments where myeloablative conditioning 
and HSCTs were performed across MHC barriers were complicated by GvHD affecting 
the skin, liver and gastro-intestinal tract. 117  However, miniature swine studies in which 
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non-myeloablative protocols were used to induce the tolerant state of mixed chimerism 
across haploidentical MHC barriers resulted in a very low incidence of GvHD. 126,227 
Conversion to full donor chimerism using donor leukocyte infusions (DLIs) was 
associated with onset of GvHD. 228  The precise mechanisms that result in absence of 
GvHD in this protocol are not known.  However, in vitro MLR data from mixed chimeras 
has previously indicated that peripheral regulation of alloreactive donor cells may 
contribute towards the absence of GvHD in this model. 229  Murine studies have also 
indicated that peripheral regulation may contribute towards the control of GvHD 
responses in the mixed chimerism setting. 230  Despite these studies, GvHD has been seen 
in clinical non-myeloablative protocols for induction of mixed chimerism. 231  Further 
work to determine the mechanisms that result in the low GvHD occurrence in the 
miniature swine model used in this study would therefore, have potentially important 
implications for the use of non-myeloablative conditioning and non-MHC identical HSCT 
in the clinical setting for both haematological malignancies and transplant tolerance.   
In this study, GvHD was seen in MHC class II-mismatched chimeric animal 
21508.  No GvHD was observed in any other MHC class II-mismatched chimeric animal 
or among MHC class I-mismatched chimeras.  Given the limited group sizes in this study, 
it is not possible to determine the role of MHC antigen sharing at class I/II antigens on 
GvHD outcomes.  In murine studies, mismatching at MHC class I has been associated 
with onset of GvHD. 232  Meanwhile immunogenetic studies have demonstrated 
heterogenous results of mismatching at various MHC class I and class II loci in clinical 
HSCT. 233  Animal 21508 received the same HSCT product as animal 21509, who did not 
develop GvHD.  However, animal 21508 demonstrated higher levels of chimerism than 
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animal 21509, or any other chimeric animal in this study.  It is thus possible that the 
HSCT product given to animal 21508 had a higher number of progenitor cells, resulting in 
higher levels of chimerism that precipitated GvHD.         
 
8.4 LONG-TERM DONOR-SPECIFIC NON-RESPONSIVENESS IS 
DEMONSTRATED IN MIXED CHIMERAS 
	
 Mixed chimeras across MHC class I and MHC class II barriers in this study 
demonstrate long-term donor-specific non-responsiveness in PBMC based in vitro assays.  
In MHC class II-mismatched chimera 22005, weak responses to donor antigens are 
detectable in MLR 200 days post-conditioning and HSCT.  Despite this, robust allograft 
tolerance to donor VCA and skin grafts is seen in this animal.   
Donor-specific non-responsiveness in vitro was demonstrated as early as 2 weeks 
post-HSCT in mixed chimeras.  Responses to third-party antigens were preserved, 
confirming that immunocompetence was maintained following conditioning.  This 
indicates than mechanisms contributing to donor-specific tolerance are operational soon 
after HSCT.   
 Retrospective analysis of miniature swine mixed chimeras generated using non-
myeloablative conditioning have identified detectable bone marrow engraftment, thymic 
chimerism and sustained peripheral chimerism in myeloid lineages as strong indicators of 
allograft tolerance.127  Mixed chimeras generated across MHC class I and class II barriers 
in this study demonstrated these parameters, confirming that robust systemic tolerance 
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was established.  Previous large animal studies and clinical trials of the mixed chimerism 
approach have demonstrated a role for both regulatory and deletional mechanisms in 
maintenance of transplant tolerance. 146,150,151  To further explore the underlying 
mechanisms contributing to tolerance in this model, CD25+ depleted CML and MLR 
assays were performed.  These showed no evidence for regulation by CD4+ CD25+ T 
regulatory cells at the systemic level.  In MLRs performed using PBMC from MHC class 
II-mismatched chimeras, addition of IL2 did not reverse donor-specific non-
responsiveness, suggesting that T cell anergy did not contribute towards systemic 
tolerance.    
  
8.5 MHC ANTIGEN MATCHING AFFECTS VCA SKIN 
TOLERANCE IN MIXED CHIMERAS  
	
I hypothesised that MHC matching between donors and recipients would affect 
VCA tolerance.  In this clinically relevant, mixed chimerism-based tolerance model long-
term tolerance of VCAs, including the skin, can be achieved across full MHC class II 
barriers.  By contrast, MHC class I-mismatched chimeras experienced rejection of VCA 
skin characterised by the infiltration of recipient-type CD8+ lymphocytes.  This is the first 
experiment identifying MHC antigen matching as a key determinant of VCA skin 
outcomes.  
MHC class I-mismatched chimeras demonstrate persistence of donor-specific non-
responsiveness in CML assays after rejection of VCA skin.  In addition, there were no 
detectable levels of IgG or IgM antibody in the systemic circulation.  Taken together this 
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indicates a lack of systemic sensitisation following rejection of VCA skin, suggesting that 
skin tolerance is mediated locally.  There has been a recent increase in understanding of 
skin-resident immunology, demonstrating a variety of resident cells within the skin such 
as macrophages, dendritic cells, Langerhans cells and resident memory T cells. 234,235  The 
presence of billions of memory T cells within the skin is driven by local inflammation and 
cutaneous infections. 236  This dense, tissue-resident immune system is able to mount 
specific localised responses in the skin without systemic help.  This includes responses 
mediated by skin-resident memory CD8+ lymphocytes. 237  It is therefore possible that the 
CD8+ lymphocytes in the skin of rejecting VCAs in MHC class I-mismatched chimeras 
are mobilised locally within the VCA, rather than being recruited from secondary 
lymphoid organs.  
The turnover of skin-resident leukocytes observed in this study is consistent with 
skin containing distinct populations of resident and re-circulating T cells. 236  In MHC 
class II-mismatched chimeras, the composition of VCA skin reaches parity with host skin.  
The presence of recipient-type lymphocytes within tolerant VCAs suggests that tolerance 
is not achieved through immune privilege.  Rather, the comparable composition of VCA 
and host skin is reflective of immune homeostasis between recipient and donor-type 
lymphocytes.  The contributions of resident and re-circulating T cells to tolerance and 
rejection cannot be determined from data in this study.  An avenue for future research is to 
characterise VCA skin-resident T cell populations and their contributions to tolerance.  
This may highlight optimal strategies to induce tolerance and treat rejection.     
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8.6 REJECTING VCA SKIN IN MHC CLASS I-MISMATCHED 
CHIMERAS IS INFILTRATED BY RECIPIENT-TYPE CD8+ T 
LYMPHOCYTES 
	
Characterisation of VCA skin-resident leukocytes in MHC class I-mismatched 
chimeras identified early infiltrate of recipient-type lymphocytes and the presence of 
recipient-type CD8+ lymphocytes in the skin during rejection.  Previous studies show that 
administration of T regulatory cells can suppress CD8+ lymphocytes during the initial T 
cell priming by alloantigen but not during the effector stage, thereby decreasing cellular 
invasion into the skin and preventing tissue damage. 238  Expeditious identification and 
targeting of alloreactive T cells may, therefore, be an important strategy to achieve clinical 
VCA tolerance. 
My findings in skin are surprising in the context of previous MGH miniature swine 
studies of solid organ transplantation where tolerance across a MHC class I disparity was 
easier to induce than across MHC class II barriers. 192,196,202  This may be due to the 
presence of MHC class I associated skin-specific alloantigens, which have been 
previously hypothesised to cause skin rejection despite tolerance of other organs. 181,239,240  
Comparing the rejected VCA skin of MHC class I-mismatched chimeras with the tolerant 
VCAs of MHC class II-mismatched chimeras or haploidentical chimeras raises the 
possibility that tolerance of skin alloantigens is mediated by presentation on self-MHC 
class I antigens. 241 
The rejection of VCA skin in MHC class I-mismatched chimeras may also be 
explained by a small subset of CD8+ T cells with a surface phenotype typical of memory 
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cells, which are found in the periphery but not the thymus, that express NK cell-like killer 
inhibitory receptors (KIRs). 242,243  Recent work has also demonstrated that potent resident 
memory CD8+ T cells exist in the skin. 237,244  It is therefore possible that infiltration of the 
skin by recipient-type memory CD8+ T cells expressing KIRs may result in the rejection 
episodes targeted towards the disparate MHC class I antigens. 
An alternative hypothesis for my VCA findings is that tolerising to allogeneic 
MHC class II antigens in MHC class II-mismatched chimeras mediates skin tolerance 
through induction of regulatory tolerance.  The presence of donor and recipient FoxP3+ 
cells was demonstrated in the VCA skin of all chimeric animals in this study.  Recent 
small animal work, in which transient depletion of FoxP3+ cells in stable chimeras 
resulted in skin rejection, indicate that Tregs may play an important role in maintaining 
tolerance of transplanted skin. 240  In other experiments, Langerhans cells in the skin have 
been shown to induce skin resident Tregs, dependent upon MHC class II antigen 
presentation. 245  Conclusively establishing whether tolerance of MHC class II antigens 
can mediate regulatory tolerance of VCA skin can be determined in future studies by 
generating mixed chimeras mismatched for one haplotype MHC class I antigens alone 
(see Section 8.13). 
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8.7 FACTORS DETERMINING THE TOLERANCE/REJECTION OF 
SKIN 
	
To investigate the underlying mechanisms that contribute to tolerance/rejection, 
mixed chimeras received non-vascularised skin grafts from donor animals and donor 
MHC-matched, miHA-mismatched animals following VCAs.  Tolerance of non-
vascularised donor skin grafts placed after VCAs was observed in MHC class II-
mismatched mixed chimeras.  MHC class I-mismatched chimeras, however, rejected non-
vascularised skin from donor animals.  
Tolerance of vascularised and non-vascularised skin in MHC class II-mismatched 
chimeras confirms robust tolerance of donor skin antigens and is in contrast to previous 
miniature swine studies where mixed chimeras rejected non-vascularised skin grafts that 
were placed in isolation. 239  The difference between these experiments suggests tolerance 
of skin antigens is aided by placing an initial vascularised allograft.  This is consistent 
with previous studies demonstrating the tolerogenic effect of presenting transplant 
antigens to the recipient using a vascularised rather than a non-vascularised route. 171,246 
All mixed chimeras rejected donor MHC-matched, miHA-mismatched skin grafts, 
but with prolonged survival seen in MHC class II-mismatched chimeras.  This 
demonstrates tolerance was induced specifically of the HSCT antigens used to generate 
mixed chimerism.  Positive CML responses were established against PBMC from donor 
MHC-matched, miHA-mismatched animals following skin graft rejection in MHC class 
II-mismatched chimeras.  Taken together with the persistence of tolerance of donor VCAs 
and non-vascularised skin in these animals, this indicates sensitisation to miHA.  
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On the other hand, positive CML responses were not established in MHC class I-
mismatched chimeras following skin rejection.  A possible explanation for this is that 
rapid rejection of donor and donor MHC-matched, miHA-mismatched skin in MHC class 
I-mismatched chimeras is mediated by skin-specific antigens not present on PBMC.  
 
8.8 TOLERANCE ACROSS FULL ALLOGENEIC MHC CLASS II 
BARRIERS MAY FACILITATE TOLERANCE BY LINKED 
SUPPRESSION  
 
The long-term survival of donor MHC-matched, miHA-mismatched skin grafts in 
MHC class II-mismatched chimeras provides proof-of-principle for linked suppression of 
miHA.  This phenomenon describes tolerance of third-party antigens when these antigens 
are co-expressed with previously tolerised antigens. 247  Linked suppression is mediated by 
regulatory T cells and requires presentation of non-tolerised and tolerised antigens in close 
proximity. 248  Prolonged survival of donor MHC-matched, miHA-mismatched skin grafts 
in comparison with recipient MHC-matched, miHA-mismatched skin grafts indicates that 
linked suppression was mediated by establishing tolerance of allogeneic MHC class II-
mismatched antigens.  This demonstration of linked suppression supports the hypothesis 
that inducing tolerance of mismatched MHC class II antigens may facilitate skin tolerance.  
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8.9 VCA SKIN TOLERANCE ACROSS MHC BARRIERS USING 
IMMUNOMODULATORY STRATEGIES  
	
Based on the proof-of-principle that generating tolerance of allogeneic MHC class 
II antigens facilitates regulatory tolerance, I investigated whether VCA skin tolerance 
could be established across MHC barriers using immunomodulatory strategies alone.  
Achieving tolerance of VCAs by induction of regulatory tolerance, facilitated by MHC 
class II antigens, would preclude the requirement for stable chimerism or intense 
conditioning and provide an important building block from which novel tolerance 
strategies can be developed.   
Following a short course of high-dose immunosuppression with calcineurin 
inhibitors, tolerance of kidneys can be established across a MHC class I disparity and a 
full MHC disparity (full MHC class I plus full MHC class II).  Tolerance in this model is 
dependent on regulatory mechanisms and can be extended to a heart co-transplanted with 
a kidney. 193,249,250  Recipients of full MHC class I-mismatched heart and kidney allografts 
who undergo kidney graftectomy and subsequent skin grafting demonstrate heart rejection 
with severe cardiac allograft vasculopathy whereas recipients of full MHC-mismatched 
(full MHC class I plus full MHC class II) heart and kidney allografts who are subject to 
the same immunologic challenge remain tolerant of their heart allografts indefinitely 
(Michel et al, manuscript in preparation).  This difference demonstrates the more robust 
regulatory mechanisms generated by the addition of tolerance of MHC class II antigens.  
Regulatory mechanisms underlying tolerance across a full MHC class I disparity 
alone are insufficient to induce tolerance of the skin component of VCAs.  Animals 
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already tolerant of MHC class I-mismatched kidney allografts rejected the epidermis of 
MHC class I-mismatched VCAs. 198  In the present study, robust regulatory mechanisms 
generated when achieving tolerance of MHC class II antigens could not induce tolerance 
of a newly placed VCA across haploidentical or full MHC mismatches.  Systemic 
regulatory mechanisms, although shown to be important for acceptance of skin in a 
humanised mouse model, are not sufficient. 251 
Animals who receive kidneys and a delayed VCA across a MHC class I barrier 
show rejection of the skin component, long-term acceptance of the muscle and 
maintenance of donor-specific unresponsiveness in vitro. 198  Animals in the present study 
who receive hearts/kidneys and a delayed VCA across a single or full MHC barrier, 
showed rejection of the skin component, rejection of the muscle and return of donor 
responsiveness by CML and MLR.  The more thorough rejection experienced both in vivo 
and in vitro across a full MHC barrier demonstrates the difficulty in establishing tolerance 
of VCAs across fully mismatched MHC barriers.  While this is unsurprising, it is still 
possible that VCA tolerance across full MHC barriers, once achieved, may be more robust 
than tolerance established across class I mismatches alone.  
Tolerance of heart and kidney allografts was maintained despite VCA rejection 
and return of in vitro evidence of donor responsiveness.  This suggests tolerance of heart 
and kidney allografts is maintained by local regulatory pathways.  However, these local 
intra-graft suppressive phenomena in the heart and kidney allografts, as well as any 
systemic regulation, are insufficient to induce tolerance of VCAs transplanted in a delayed 
fashion. 197,252-255  
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This study demonstrates that a robust regulatory milieu alone is insufficient to 
achieve tolerance of VCAs.  Achieving tolerance of VCAs is more difficult to achieve 
than tolerance of hearts or kidneys and strategies that can establish robust tolerance with 
acceptable risks are required.  
 
8.10 RELEVANCE OF MINIATURE SWINE MODELS 
	
 In comparison to mouse studies, miniature swine models are harder to use, offer 
less control of experimental conditions, are less reproducible and less able to clearly 
delineate basic immunological mechanisms.  However, the clinical applicability of murine 
studies of transplantation is significantly limited by the lower threshold for induction of 
tolerance in comparison with humans.  MGH miniature swine studies, on the other hand, 
have already demonstrated an important position in the translation of the mixed chimerism 
based approach for transplant tolerance into clinical trials.   
It is important to consider that differences between human and pig immune 
systems do exist, including the higher proportion of γδ T cells in the peripheral circulation 
of pigs. 256  However, in comparison with mice, the porcine immune system more closely 
resembles the human for greater than 80% of analysed parameters. 257  The cellular 
components of the human immune system can be found in pigs.  Similar to humans, and in 
contrast with mice, pigs have high percentages of neutrophils in the peripheral blood. 258  
In addition the function of pig Th1/Th2/Th17/Treg cells, including cytokine-signaling 
pathways, resemble the human. 257  Finally, components of the innate immune system 
including monocytes, neutrophils and dendritic cells (including toll-like receptor 
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expression) are similar in pigs and humans. 257,259  The similar immunogenic 
characteristics of the MHC complex and the similar complexity of the innate and adaptive 
immune systems make miniature swine a suitable model for translational studies in 
transplantation immunology.   
Outside of the immune system, the homology between the size, physiology and 
organ function of pigs and humans make swine models relevant to human diseases.  In a 
particular advantage for VCA, the skin of miniature swine is similar in structure and 
function to humans.  Similarities include overall thickness, ratio of epidermis to dermis 
thickness, dermal blood supply pattern, subdermal fat composition and hair follicle 
density. 260  As a result miniature swine have provided useful clinical models for wound 
healing and skin diseases affecting humans, such as burns, dermatological diseases and 
cutaneous GvHD. 227,260  The characterisation of skin resident leukocytes in miniature 
swine skin in this study reveals higher proportions of CD4+ lymphocytes than CD8+ 
lymphocytes, comparable to human skin.  The clinical and histological features of 
rejecting porcine skin resemble human VCA skin rejection. 221        
 
8.11 CLINICAL IMPLICATIONS 
	
 The results of this study may have implications for the selection of donors and 
recipients chosen for VCA tolerance protocols.  As VCA transplantation is not a life-
saving intervention, short-listing potential recipients and waiting for an appropriately 
matched donor would be theoretically possible.  However, given that the overall volume 
of donors and recipients for VCA transplantation is relatively low, MHC matching may 
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serve to restrict rather than expand the field.  On the other hand, delineating the underlying 
mechanisms resulting in the disparate VCA outcomes seen across MHC class I and MHC 
class II barriers in this study may identify potential targets for therapies promoting 
transplant tolerance.   
 The non-myeloablative protocol for induction of mixed chimerism used in this 
study, consisting of T cell depletion, TBI, HSCT and a course of immunosuppression 
using CyA, has the potential for translation into a clinical protocol.  Special consideration, 
however, must be given to its applicability to VCA.  Given VCAs require deceased 
donors, extensive pre-conditioning, including the mobilisation of large numbers of donor 
CM-PBSC, will not be possible.  Solutions to this problem include development of a day 0 
protocol in which T cell depletion, TBI and HSCT using BMT are performed on the day 
of VCA transplantation.  Another elegant strategy involves delayed protocols, where 
VCAs are transplanted under the cover of conventional immunosuppression and donor 
bone marrow is acquired, frozen and stored.  Tolerance induction protocols are 
subsequently performed in a delayed manner.  This approach has been successfully 
attempted in non-human primate studies of solid organ transplantation, providing 
optimism that similar protocols can be developed for VCA transplantation. 137 The 
applicability of the findings in this study is thus reliant on the development, refinement 
and translation of applicable mixed chimerism based tolerance protocols from large 
animals to clinical trials.   
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8.12 LIMITATIONS 
	
Given that VCAs are life-enhancing rather than life-saving, risks related to 
induction of transplant tolerance must be minimised.  Chimerism remains the only 
approach to have established transplant tolerance in large animal and clinical studies and 
the use of immunomodulatory strategies alone has been unsuccessful. 130,146  The use of 
mixed chimerism for transplant tolerance has inherent risks related to conditioning and 
GvHD.  In this study, conditioning-related complications of sepsis and anaemia were 
observed, resulting in death of animals.  In addition, acute and chronic GvHD was seen in 
a MHC class II-mismatched chimera.  Previous studies using mixed chimerism for 
transplant tolerance across MHC barriers have shown occurrence of GvHD in as many as 
30% of cases. 191  Clinical regimens that generate mixed chimerism have similarly carried 
up to a 34% risk of GvHD and complications of opportunistic infections have been 
observed. 261,262  Thus, the complications of the chimerism approach must be carefully 
considered against the quality of life advantages of VCA before the results of the present 
study can be applied to clinical tolerance protocols.  
Juvenile animals were used for the mixed chimerism experiments to permit 
adequate, weight-adjusted doses of CM-PBSCs to be achieved.  The use of smaller 
recipient animals additionally served the purpose of minimising the total volume of 
reagants used for mobilisation of HSCT and T cell depletion, limiting overall costs.  The 
induction of tolerance in animals with a juvenile thymus, and the mechanisms underlying 
tolerance, may be different to the more clinically common scenario of adult recipients.  
While previous experiments have indicated that achieving mixed chimerism-based 
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tolerance in adult recipients can be achieved, repeating the present study using adult 
recipients would provide a useful additional experiment. 
It is important to analyse alternative factors that may have influenced our results in 
mixed chimeras.  The role of miHA should be considered.  It is possible that miHA, not 
expressed on HSCT, can mediate VCA rejection and GvHD.  The MGH miniature swine 
programme is designed to maintain miHA variances between animals within lines 
(Methods: section 4.1).  However, given that the herd is inbred, it is possible that certain 
miHA have become fixed within lines.  Due to breeding constraints and availability of 
animals, we used the same donor/recipient strain combinations in each group to create 
MHC class I (SLAgg donors/SLAdd recipients) and MHC class II (SLAgg donors/SLAcc 
recipients) barriers.  Differences in the sharing of miHA between SLAgg donors and SLAdd 
recipients, not shared by SLAgg donors and SLAcc recipients may, therefore, have an effect 
on allograft survival and GvHD outcomes.  This can be addressed in future studies by 
using different lines of MGH miniature swine to create MHC class I/class II differences. 
Another factor that could influence the results of the mixed chimerism studies in 
this thesis is gender differences between donors and recipients.  By chance and 
availability, all donor/recipient combinations in the MHC class I mismatched group 
involved male donors and female recipients.  It is possible that Y chromosome-linked 
antigens may have resulted in rejection outcomes.  It is important to note that previous 
MGH miniature swine experiments using non-myeloablative conditioning to induce mixed 
chimerism and transplant tolerance, of solid organs and VCAs, have involved male donors 
and female recipients.  This provides reassurance that the outcomes seen in MHC class I-
mismatched chimeras are unlikely to be related to gender differences alone. 
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In this experiment, a MHC class II-mismatched chimera (21509) developed a line 
site infection requiring treatment with antibiotics.  This animal demonstrated long-term 
VCA tolerance.  The potential influence of infections and inflammatory reactions on our 
results should be mentioned.  Given that recipient animals of HSCT were juvenile, 
exposure to infections may have had an impact on the development of the T cell 
repertoire.  This is an important consideration for experiments of skin immunology, due to 
the extensive numbers of memory T cells in the skin.  To minimise the impact of 
infections on the study results, MGH miniature swine were bred in a pathogen-free facility 
and recipients of HSCT were kept in cages with HEPA filters.  
Large animal studies are limited by the number of animals used, preventing 
statistical evaluation between groups.  While analysis of underlying tolerance/rejection 
mechanisms has been attempted, in vitro studies in large animal models have limitations.  
Further work in mouse models may prove beneficial in delineating the underlying 
mechanisms behind MHC class I associated skin rejection and the local mechanisms that 
may lead to tolerance.  The demonstration of donor-specific non-responsiveness on MLR, 
CML and alloantibody assays, despite VCA rejection, may be due to sequestration of anti-
allograft lymphocytes or antibodies in the allograft.  Alternatively, in vitro assays may not 
reflect in vivo immunobiology.  
Clinical trials in transplantation based on experimental findings in miniature swine 
have occurred.  Despite this, VCA tolerance protocols using the mixed chimerism 
approach will need translation via non-human primate studies due to the close species 
homology to humans, the need for further protocol iteration and long-term follow-up.  
Given that studies in non-human primates would be required, the relevance of miniature 
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swine experiments can be questioned.  However, the present study in miniature swine has 
revealed new observations pertaining to skin tolerance.  The increased understanding of 
the role of MHC antigen matching in VCA skin tolerance, acquired through this swine 
model, may help with the design and development of VCA tolerance studies in non-
human primates, accelerating translation to clinical trials in the future.   
 
8.13 FUTURE WORK 
 
In this study, we have demonstrated tolerance of VCAs in MHC class II-
mismatched chimeras and rejection of VCA skin in MHC class I-mismatched chimeras.  
Future work can be done to further investigate the mechanisms underlying the differential 
effects of MHC class I versus MHC class II mismatching.  
Based on the data from the present study, it can be hypothesised that MHC class I 
mismatching between donor and recipient mediates a rejection response in VCA skin or 
that mismatching for MHC class II may mediate VCA skin tolerance, via induction of a 
regulatory pathway.  Future work can determine whether acceptance of the skin of VCAs 
is due to sharing of MHC class I antigens between donors and recipients, or due to 
mismatching of MHC class II antigens.  The MGH miniature swine, which have fixed 
MHC loci is a unique large animal model in which F1 animals can be generated by cross 
breeding between lines. 203  This will allow generation of donors and recipients that are 1-
haplotype MHC class I-mismatched and fully matched for class II antigens (Figure 8.1).  
Rejection of VCA skin in mixed chimeras in this setting would identify MHC class II 
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mismatching as the key determinant of skin tolerance.  On the other hand VCA skin 
tolerance would indicate that MHC class I sharing facilitates tolerance.   
 
 
Figure 8.1.  MGH miniature swine D/G F1 animal experimental model. 
Through cross breeding of MGH miniature swine between lines, D/G F1 animals can be 
generated.  Donors and recipients can then be selected that are fully matched at MHC 
class II antigens and mismatched at a single haplotype at MHC class I antigens.  This 
would determine whether MHC class I sharing versus MHC class II mismatching 
facilitates VCA skin tolerance.  
 
Animal models of stable hematopoietic chimerism have shown central deletion as 
the primary method of transplant tolerance. 111,191,263  Consistent with this, chimeric 
animals across MHC class I and MHC class II barriers demonstrate no evidence of 
systemic regulation, with persistence of donor-specific non-responsiveness in vitro in 
CD25+ depleted CML and MLR assays.  The VCA outcomes of MHC class I-mismatched 
chimeras, thus, raises interesting questions about the underlying immunological 
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mechanisms governing skin rejection.  Characterisation of VCA skin-resident leukocytes 
in MHC class I-mismatched chimeras identified early infiltrate of recipient-type 
lymphocytes and the presence of recipient-type CD8+ lymphocytes in the skin during 
rejection.  It is possible that the early lymphocyte infiltrate contained non-deleted 
alloreactive cells, which persist locally within the VCA and mediate skin rejection once 
the immunosuppression is tapered.  This can be further studied in future experiments 
where VCAs are transplanted in a delayed fashion in MHC class I-mismatched chimeras, 
following establishment of tolerance.  VCA rejection in this setting would indicate that 
rejection is triggered by antigens in the skin but not in the hematopoietic stem cells used to 
generate chimerism.  In contrast, skin acceptance of VCAs placed after establishment of 
deletional tolerance in MHC class I-mismatched chimeras would signify that the early 
lymphocytic infiltrate into the VCA, seen in the current study, is the cell population that 
causes skin rejection.  This experiment would help identify cellular targets for therapies, 
such as anti-CD8 monoclonal antibodies, that may facilitate induction of VCA tolerance.  
 
8.14 CONCLUSIONS 
	
In this study I have identified that MHC antigen matching is a critical determinant 
of VCA skin tolerance.  MHC class II-mismatched chimeras were tolerant of VCAs, while 
MHC class I-mismatched chimeras rejected VCA skin.  This study suggests that local 
regulation of immune tolerance is critical in long-term acceptance of all VCA 
components.  Furthermore, we have demonstrated that miHA-mediated rejection of skin 
grafts can be mitigated by linked-suppression, achieved by inducing tolerance across full 
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MHC class II antigen barriers.  However, a robust systemic regulatory milieu alone, 
generated by induction of tolerance of allogeneic MHC class II antigens, was insufficient 
to achieve tolerance of VCA skin.  
These data provide novel insights into factors that mediate the tolerance/rejection 
of transplanted skin with potential implications for VCA tolerance strategies and the 
selection of donors and recipients chosen for such protocols.  
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MONITORING CHIMERISM IN MHC CLASS I/II MISMATCHED 
CHIMERAS FOLLOWING HSCT 
	
Chimerism in the peripheral blood was monitored using flow cytometry.  Donors 
and recipients were mismatched for a non-histocompatibility antigen (PAA) to allow 
tracking of donor and recipient populations in multiple lineages.  Example flow plots are 
demonstrated in this appendix showing the establishment and persistence of mixed 
chimerism in MHC class I-mismatched chimeras and MHC class II-mismatched chimeras 
at multiple time-points. 
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Appendix Figure 1.  Week 4 chimerism for MHC class I-mismatched chimeric animal 21656 
demonstrated on flow cytometry in a) CD8+ and CD4+ lymphocyte, b) granulocyte, c) monocyte 
and d) NK cell lineages.  
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Appendix Figure 2.  Post-day 50 chimerism for MHC class I-mismatched chimeric animal 21656 
demonstrated on flow cytometry in a) CD8+ and CD4+ lymphocyte, b) granulocyte, c) monocyte 
and d) NK cell lineages.  
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Appendix Figure 3.  Post-day 100 chimerism for MHC class I-mismatched chimeric animal 
21656 demonstrated on flow cytometry in a) CD8+ and CD4+ lymphocyte, b) granulocyte, c) 
monocyte and d) NK cell lineages.  
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Appendix Figure 4.  Week 4 chimerism for MHC class II-mismatched chimeric animal 21509 
demonstrated on flow cytometry in a) CD8+ and CD4+ lymphocyte, b) granulocyte, c) monocyte 
and d) NK cell lineages.  
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Appendix Figure 5.  Post-day 50 chimerism for MHC class II-mismatched chimeric animal 21509 
demonstrated on flow cytometry in a) CD8+ and CD4+ lymphocyte, b) granulocyte, c) monocyte 
and d) NK cell lineages.  
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Appendix Figure 6.  Post-day 100 chimerism for MHC class II-mismatched chimeric animal 
21509 demonstrated on flow cytometry in a) CD8+ and CD4+ lymphocyte, b) granulocyte, c) 
monocyte and d) NK cell lineages.  
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